

Prof. Flavio Luciano Ribichini

***Curriculum dell'attività scientifica,
didattica e clinica.***

Gennaio 2017

Un curriculum è, di solito, un elenco delle azioni compiute e dei risultati ottenuti nel corso della carriera e che il candidato ritiene importanti e giusti. Questi vengono dichiarati pubblicamente al solo scopo di farsi conoscere dagli altri, come richiesto dalla nostra società e dai i suoi parametri di valutazione. Il curriculum non descrive mai gli errori, ne' mette in rilievo le persone che ci hanno aiutato a raggiungere gli obbiettivi dei quali andiamo fieri.

Mettendo in chiaro che ho imparato più dagli errori che dai successi e che devo quanto ho potuto fare alle persone che mi hanno supportato dandomi l'opportunità di mettermi alla prova, dichiaro quanto segue:

Indirizzo privato

Via A.G. Venturelli n° 3
37128 - Verona
e-mail: flavio_ribichini@hotmail.com

Luogo e data di nascita

Cordoba (Argentina), 28 Maggio 1963

Stato civile

Sposato con Valeria
3 figli bellissimi (come la madre)

Posizione professionale attuale

**Professore Associato di Malattie dell'Apparato Cardiovascolare
Idoneo Professore di I° fascia (Ordinario)**

Dipartimento di Medicina
Università di Verona

Direttore FF della UOC a Direzione Universitaria di Cardiologia

Divisione di Cardiologia
Azienda Ospedaliera Universitaria Integrata di Verona
Ospedale Civile Maggiore
Piazzale Stefani, 1
37126 - Verona
Telefono: 045/812 2320 (segreteria)
E-mail: flavio.ribichini@univr.it

Direttore della S.S. di Emodinamica ed Interventistica Cardiovascolare dal 2006

Divisione di Cardiologia
Azienda Ospedaliera Universitaria Integrata di Verona
Ospedale Civile Maggiore
Piazzale Stefani, 1
37126 - Verona
Telefono: 045/812 2039
E-mail: flavio.ribichini@univr.it

Direttore della Scuola di Dottorato di Scienze della Vita e della Salute dell'Università di Verona.

Strada delle grazie 8
37135- Verona
Segreteria: Laura Marcazzan
Telefono: 045 802 7026
E-mail: laura.marcazzan@univr.it

Direttore della Scuola di Specializzazione in Malattie dell'Apparato Cardiovascolare dell'Università di Verona.

Piazzale Aristide Stefani 1
37126- Verona
Segreteria: Crsitina Bertani
Telefono: 045 812 3077
E-mail: clinica.cardiologica@ospedaeuniverona.it

1. Educazione

- 1976-1980 Liceo Scientifico "Dean Gregorio Funes", Còrdoba, Argentina (dove studiò Ernesto Guevara de la Serna).
- 1981-1986 Corso di laurea in Medicina e Chirurgia, Universidad Nacional de Còrdoba, Argentina. Laureato con lode il 3 dicembre 1986.
- 1986-1988 Specializzando interno di Medicina Interna Centro Medico HP di Còrdoba, Argentina.
- 1988-1989 Borsista del Ministero degli Affari Esteri presso il Dipartimento di Scienze Biomediche dell'Università di Torino.
- 1989 Laurea in Medicina e Chirurgia, con lode, Università di Torino
- 1989-1992 Scuola di Specializzazione in Cardiologia, Università di Torino.

2. Esperienza professionale formativa

Comando di perfezionamento, presso l'Unità di Cardiologia Emodinamica dell'Ospedale Multizonale di Circolo di Varese E. Macchi dal 10-11-1991 al 28-02-1992.

Stage di perfezionamento in angioplastica coronarica percutanea, presso il Centro Policlinique Les Alpilles, Marsiglia, Francia, dal 05-04-1993 al 07-05-1993

Stage di perfezionamento in angioplastica coronarica percutanea e stenting coronarico, presso l'Hopital Henri Mondor, Universtè de Paris, Creteil, Francia dal 14-02-1994 al 14-3-1994.

Stage di perfezionamento in cardiologia interventistica ed ecografia vascolare intracoronarica, presso l'Unità di Cardiologia Invasiva dell'Università di Stanford, e stage presso il Center for Research in Cardiovascular Interventions della Stanford University, School of Medicine, California USA dal 12-11-1995 al 09-12-1996.

Stage di perfezionamento in cardiologia interventistica (aterectomia direzionale, rotazionale e TEC) presso il Cardiovascular Institute del Mount Sinai Medical Center, New York, dal 28-10-1996 al 08-11-1996.

Stage di perfezionamento in cardiologia interventistica, con particolare dedizione alla radioterapia intracoronarica, aterectomia rotazionale, ecografia intravascolare, pressioni e flussi endocoronarici (FFRMyo e CFR), ablazioni di rami settali per il trattamento della cardiomiopatia ipertrofica ostruttiva, presso il Cardiovascular Center del OLV Hospital in Aalst, Belgio, dal 1-01-1997 al 31-05-1998.

Stage lavorativo presso l'Institute of Cardiovascular Pathology del Armed Force Institute of Pathology (AFIP), Washington DC a Maggio 2000 per imparare tecniche istologiche di studio della malattia coronarica.

3. Esperienza professionale clinica- assistenziale

Assistente medico di Medicina Interna a tempo pieno, presso il Centro Medico di Cordoba dal 1 Maggio 1987 al 11 Ottobre 1988. Tale attività lavorativa è stata riconosciuta dal Ministero della Sanità Italiana come servizio sanitario prestato all'estero con D.M del 12 agosto 1994. Ai fini dell'anzianità di servizio, vi è anche il riconoscimento dell'Ospedale Santa Croce e Carle di Cuneo.

Consulente Cardiologico, presso l'Ospedale Valdese di Torre Pellice (TO) dal 1 Maggio 1991 al 4 settembre 1991, svolgendo attività di clinica ambulatoriale e di ecocardiografia.

Dirigente medico di primo livello di Cardiologia in carica, a tempo pieno, presso l'Ospedale Santa Croce di Cuneo dal Settembre 1991, in servizio presso il Laboratorio di Emodinamica dal 20-07-1992 fino al 28-02-2002. Assistente Medico Cardiologo a tempo pieno dal 09/09/1991 al 31/12/1992, poi Medico di 1 Livello Dirigenziale fascia B, cardiologia di ruolo a tempo pieno dal 01/01/1993 al 05/12/1996, poi Dirigente Medico 1 Livello Cardiologia a tempo indeterminato a tempo pieno dal 06/12/1996 al 30/07/1999; poi Dirigente Medico Cardiologia a tempo pieno indeterminato a tempo pieno dal 31/07/1999 al 28/02/2002. Il 01/03/2003 cessato il rapporto per dimissioni volontarie.

In 10 anni di servizio di ruolo presso l'Ospedale Santa Croce e Carle di Cuneo e nei periodi di perfezionamento all'estero, eseguite circa 1500 interventi coronarici percutanei e più di 5000 cateterismi diagnostici come primo operatore. Inoltre, ha contribuito alla formazione in cardiologia invasiva diagnostica ed interventistica di specializzandi e medici frequentatori provenienti da altri ospedali.

Si segnala in particolare l'avvio del servizio di reperibilità di emodinamica 24 ore / 24 per il trattamento dell'infarto acuto di miocardio come primo operatore di angioplastica primaria dal 1992, tra i primi di questo genere in Italia, come attestano le pubblicazioni scientifiche in merito (*vedi pubblicazioni numero 18,22,24,25,29,32 dall'elenco di pubblicazioni allegato*).

Tra le tecniche diagnostiche di cardiologia invasiva, conoscenza di metodiche ecografiche intracoronariche, di studio di flusso e pressioni con Doppler intracoronarico e guide pressorie.

Tra le tecniche interventistiche, oltre all'uso convenzionale di protesi intracoronariche, esperienza con aterectomia direzionale e rotazionale, utilizzo di sistemi di brachiterapia intracoronarica con sorgenti beta emittenti, uso di guide a radiofrequenza e sistemi distali di protezione. Inoltre, dal 2000 attività di chiusura dei forami ovali pervi con dispositivo Amplatzer.

Dal 1 Marzo 2002 Ricercatore presso la Clinica Cardiologia dell'Ospedale Maggiore della Carità di Novara, afferente al Dipartimento di Scienze Mediche della Facoltà di Medicina dell'Università del Piemonte Orientale.

Con la stessa decorrenza, incarico come Direttore dell'Unità Didattico Assistenziale (UDA) - a valenza Dipartimentale- di Cardiologia Interventistica e Diagnostica Invasiva dell'Università del Piemonte Orientale, dove ha eseguito come primo operatore o come co-operatore responsabile (tutor) oltre 1800 cateterismi cardiaci diagnostici ed oltre 760 interventi coronarici percutanei (secondo dati pubblici del registro della Società Italiana di Cardiologia Invasiva).

Come dirigente medico della Clinica Cardiologica ha effettuato le guardie di reparto e di pronto soccorso in numero identico al numero di guardie eseguite dai medici ospedalieri dello stesso reparto. Inoltre, partecipa, seppur in minor misura, all'attività dell'ambulatorio divisionale, della corsia ed del servizio di Day-Hospital del reparto.

Dal 1 Marzo 2006 Responsabile del Laboratorio di Cardiologia Diagnostica Invasiva ed Interventistica della Divisione Clinicizzata di Cardiologia dell'Università di Verona, presso l'Ospedale Maggiore di Borgo Trento di Verona.

L'unità di Emodinamica ed Interventistica Cardiovascolare della AOUI di Verona, esegue circa **2000 casi per anno, dei quali 800 interventi endovascolari, coronarici e periferici**. Garantisce un **servizio di emergenza cardiocvascolare alla popolazione della città di Verona e dintorni (circa 500.000 abitanti) 24 ore/365 giorni**. E' centro provinciale di riferimento per l'angioplastica primaria, l'interventistica pediatrica e l'interventistica cardiaca strutturale. E' **centro di riferimento Regionale per la denervazione renale**, ed è centro di formazione per tecniche di diagnostica invasiva (IVUS, FFR), interventistica complessa coronarica e periferica (aterectomia rotazionale, sistemi di supporto circolatorio), interventistica valvolare mitralica e aortica.

Nel periodo 2006-2016 ha eseguito come primo operatore, o come tutor di cardiologi in training oltre 7000 cateterismi cardiaci e vascolari periferici, dei quali oltre 3500 angioplastiche coronariche e periferiche, anche associate ad ecografie intravascolari o a sistemi di supporto circolatorio extracorporeo (Impella o Ecmo in 40 casi), oltre 400 impianti di valvole aortiche, 100 valvuloplastiche aortiche, mitraliche, polmonari e tricuspидali. Tali dati sono consultabili presso i registri di sala operatoria del laboratorio.

Consulente cardiologo per la Divisione di Cardiochirurgia

Consulente cardiologo per la Terapia Intensiva Generale

Dal 2006 effettua regolare attività mensile come cardiologo di guardia della Divisione di Cardiologia per l'Ospedale, incluso il Pronto Soccorso.

4. Carriera accademica

Marzo 2002: Ricercatore Universitario di Cardiologia, SSD Med 11, presso l'Università del Piemonte Orientale.

Marzo 2005: Ricercatore confermato,

Dicembre 2006: Professore Associato di Cardiologia, SSD Med 11, presso l'Università di Verona.

Dicembre 2009: Professore Associato confermato.

Dicembre 2013: Abilitazione Nazionale del MIUR come idoneo Professore di Prima Fascia di Cardiologia e Malattie dell'Apparato Cardiovascolare (SSD MED 11).

Dicembre 2013-Dicembre 2016: Direttore della Scuola di Dottorato di Scienze della Vita e della Salute dell'Università di Verona.

Da Luglio 2017: Direttore della Scuola di Specializzazione in Malattie dell'Apparato Cardiovascolare dell'Università di Verona.

5. Conoscenze linguistiche

Italiano, *livello: buono*

Inglese, *livello: buono*

Spagnolo, *livello: buono*

Francese, *livello: buono*

Portoghese, *livello: buono*

6. Attività didattica

Università Nazionale di Córdoba, Argentina

1985-1986: Coadiutore per le esercitazioni di Semeiotica Medica. Corso di Laurea in Medicina, Università di Córdoba

Università del Piemonte Orientale

Corso di Laurea in Medicina e Chirurgia

Titolare dall'aa 2004-2005 dell'insegnamento di Cardiologia nel corso integrato di Patologia Integrata Medica al IV anno.

Corso di Laurea in Fisioterapia

Titolare dall'aa 2002-2003 e per 4 anni accademici consecutivi dell'insegnamento di malattie dell'apparato cardiovascolare nel corso integrato di Riabilitazione cardio-respiratoria.

Corso di Laurea in Infermieristica

Titolare dall'aa 2003-2004 dell'insegnamento e per 2 anni consecutivi di malattie dell'apparato cardiovascolare nel corso integrato di Metodologia infermieristica applicata alla medicina specialistica.

Corso di Laurea in Biotecnologie Mediche e Farmaceutiche

Titolare dall'aa 2004-2005 dell'insegnamento di cardiologia e protesi endotissutali

Scuola di Specializzazione in Cardiologia

Titolare dall'aa 2002-2003 e negli anni successivi fino al 2005-2006 dei corsi:

- Terapia Intensiva
- Cardiologia Interventistica
- Diagnostica Invasiva

Università di Verona

Scuola Medicina e Chirurgia	Cardiopneumopatologia (2014/2015)	8	2	FISIOPATOLOGIA DEL SISTEMA CARDIO CIRCOLATORIO
Scuola Medicina e Chirurgia	Infermieristica clinica in area medica [<i>Matricole dispari</i>] (2014/2015)	8	1	MALATTIE CARDIOVASCOLARI
Scuola Medicina e Chirurgia	Patologia sistematica II (2014/2015)	18	0,5	CARDIOLOGIA E CHIRURGIA CARDIOVASCOLARE DIDATTICA
Scuola Medicina e Chirurgia	Riabilitazione viscerale I (2014/2015)	8	1	PRATICA DI NEFROLOGIA, ENDOCRINOLOGIA, CARDIOLOGIA [Gruppo Cardiologia Prof. Ribichini]
Scuola Medicina e Chirurgia	Tecniche cardiovascolari invasive (2014/2015)	4	2	CARDIOLOGIA DIAGNOSTICA E PROCEDURE CARDIOVASCOLARI INVASIVE

Scuola Medicina e Chirurgia	Cardiopneumopatologia (2013/2014)	8	2	FISIOPATOLOGIA DEL SISTEMA CARDIO CIRCOLATORIO
Scuola Medicina e Chirurgia	Infermieristica clinica in area medica [<i>Matricole dispari</i>] (2013/2014)	8	1	MALATTIE CARDIOVASCOLARI
Scuola Medicina e Chirurgia	Patologia sistematica II (2013/2014)	18	0,5	CARDIOLOGIA E CHIRURGIA CARDIOVASCOLARE DIDATTICA PRATICA DI NEFROLOGIA, ENDOCRINOLOGIA, CARDIOLOGIA [Gruppo Cardiologia Prof. Ribichini]
Scuola Medicina e Chirurgia	Riabilitazione viscerale I (2013/2014)	8	1	CARDIOLOGIA
Scuola Medicina e Chirurgia	Tecniche cardiovascolari invasive (2013/2014)	4	2	DIAGNOSTICA E PROCEDURE CARDIOVASCOLARI INVASIVE

Scuola di Specializzazione in Malattie dell'Apparato Cardiovascolare
 Titolare dall'aa 2006-2007 del corso di Emodinamica e Cardiologia Interventistica:

Scuola di Specializzazione in Immunologia

Titolare dall'aa 2008-2009 del corso di Cardiologia:

Scuola di Dottorato in Scienze della Vita e la Salute

Insegnamento di Cardiologia

Scuola di Dottorato in Scienze Cardiovascolari

Insegnamento di Cardiologia Interventistica

Scuola di Specializzazione in Geriatria

Insegnamento di Cardiologia

Scuola di Specializzazione in Pediatria

Insegnamento di Cardiologia

7. Attività scientifica

L'attività scientifica ha riguardato diversi aspetti della patologia vascolare, cardiaca, ed extra-

cardiaca, sia dal punto di vista fisiopatologico che terapeutico. In particolare le aree di ricerca sviluppate sono state le seguenti:

1. Trattamento dell'infarto acuto con angioplastica primaria, ed in modo particolare, l'angioplastica primaria senza supporto cardiocirurgico in sede.
2. La genetica della restenosi intrastent e della malattia coronarica giovanile.
3. La terapia immunosoppressiva sistemica come approccio anti-restenotico ed anti-aterosclerotico.
4. Lo studio istologico in vivo della placca aterosclerotica ed in particolare il ruolo del sistema renina-angiotensina nella restenosi intra-stent.
5. Aspetti diagnostici clinici della stenosi aortica.
6. La malattia vascolare pluridistrettuale coronarica e carotidea.
7. L'associazione tra difetti cardiaci e l'ictus giovanile criptogenetico e l'associazione tra sindromi coronariche acute ed ischemia cerebrovascolare.
8. La diagnosi emodinamica/ecocardiografica della stenosi valvolare aortica, ed il trattamento transcateretere delle cardiopatie valvolari nel paziente anziano ed ad alto rischio.
9. La diagnosi intravascolare ecografica della coronaropatia e lo studio funzionale dell'ischemia inducibile con fractional flow reserve.
10. La nefropatia correlata alle tecniche transcateretere e la somministrazione di mezzo di contrasto.
11. La rivascolarizzazione miocardica del paziente complesso o multivasale, inclusive di sistemi di supporto circolatorio.
12. Il trattamento dello scompenso cardiaco acuto
13. La denervazione renale in pazienti con ipertensione arteriosa resistente.
14. Studi di fisiologia coronarica in vivo in pazienti affetti da stenosi valvolare aortica e concomitante patologia vascolare coronarica.
15. Trapianto Cardiaco e trattamento dello scompenso e della malattia coronarica dell'allograft (CAV).
16. Endoportesi vascolari bio-assorbibili.
17. Linee Guida Internazionali (ESC ACC AHA)

L'attività di ricerca ha dato origine a:

Oltre 200 lavori *in extenso* pubblicati su riviste censite da ISI e con Impact Factor (di cui oltre un terzo come primo o ultimo autore) (vedi tabella sinottica)

Oltre 500 relazioni su invito a convegni e congressi nazionali ed internazionali e seminari presso istituzioni nazionali ed internazionali. In molti casi, in ogni convegno o congresso sono state presentate più di una relazione scientifica.

I lavori pubblicati hanno avuto 7490 citazioni (fonte Scopus) e l'Impact Factor complessivo è di 1030. L'indice H (Hirsch Index) è 30 (fonte Scopus, lavori pubblicati dal 1992).

8. Partecipazione a Task Forces delle Linee Guida Internazionali (ESC AHA ACC)

AHA ACC Guidelines on Cardio-Pulmonary Resuscitation. Circulation 2000. Author of the Chapter: Primary PCI in ST-segment elevation myocardial infarction.

ESC Guidelines on Myocardial Revascularization: Eur Heart J 2010. Author.

ESC Guidelines on Peripheral Artery Disease: Eur Heart J 2012. Scientific Reviewer

ESC Working Group on Stroke 2016: Member

ESC Guidelines on Myocardial Revascularization (update) 2018: Scientific Reviewer

9. Attività di consulenza per aziende del settore interventistico endovascolare.

Dal 1999 è membro del Medical Advisory Board italiano di Guidant, e successivamente di Abbott Vascular per il settore coronarico, e dal 2012, dell'European Medical Advisory Board per la Vascular Reparative Therapy.

Dal 2010 è membro dell'European Medical Advisory Board di Medtronic per il settore coronarico, periferico, strutturale e di denervazione renale.

Dal 2011 è proctor internazionale di Edwards Lifescience per l'insegnamento delle tecniche di impianto valvolare trans-catetere (TAVI).

Nel 2012-2013 membro dell'European and US medical advisory board di Boston Scientific per il progetto di bioresorbable polimer drug-eluting stent, e membro del european expert consensus group sulla aterectomia rotazionale.

Dal 2012 è proctor e consulente Europeo di Volcano per la diagnosi ecografica intravascolare e le tecniche di valutazione fisiologica dei flussi coronarici (fractional flow reserve, FFR e iFR)

Dal 2013, membro dell'european expert consensus group di ABIOMED sull'assistenza ventricolare sinistra percutanea con dispositivo IMPELLA, e proctor italiano per l'insegnamento delle tecniche di supporto circolatorio trans-catetere.

Dal 2015 Membro dell'International Medical Advisory Board di SORIN Biomedica.

Dal 2016 è proctor internazionale di Medtronic per l'insegnamento delle tecniche di impianto valvolare trans-catetere auto-espandibili (TAVI).

Dal 2016, membro dell'International Medical Advisory Board di Philips-Volcano.

10. Borse di studio, premi e riconoscimenti

Premio della Società Italiana di Cardiologia Invasiva (GISE) al miglior lavoro scientifico dell'anno 1997 per la ricerca intitolata: "Comparison of thrombolytic therapy and primary angioplasty with liberal use of stenting, a randomized study. Pubblicato in J Am Coll Cardiol 1998;32:1687-1694.

Vincitore di un Research Fellowship de la Società Europea di Cardiologia per lo sviluppo del progetto di ricerca di marcatori genetici della restenosi. Pubblicato in Circulation 1998;97:147-154.

Vincitore del premio annuale "Larramendi" nell'a.a 1999-2000 della Società Spagnola MAPFRE per il progetto di ricerca con brachiterapia intracoronarica ed il trattamento radiante geneticamente guidato. The BetACE randomized trial. Pubblicato in CRM 2005;6:7-13.

Premio 2008 della Russian Scientific Society of Interventional Radiology and Endovascular Surgery.

Primo premio SOLACI 2010 de la Società Latinoamericana di Cardiologia Intervencionista, Buenos Aires 11 Agosto 2010 per il lavoro: Clinical outcome after endovascular, surgical, or hybrid revascularization in patients with combined carotid and coronary artery disease. Pubblicato in Eurointervention 2010;6:328-335.

Premio 2010 della Società Serbia di Cardiologia

Premio TCT Award Best Challenging case 2011, 11 Novembre, San Francisco, California, US per il lavoro: Transfemoral Edwards-Novaflex valve implantation in a patient with aortoiliac endoprosthesis and severely tortuous bilateral external iliac arteries-"Railing track". Pubblicato in Cardiovasc Revasc Med. 2012;13:203.e5-8.

Premio TCT Award Best Challenging case 2013, 1 Novembre, San Francisco, California, US per il lavoro: Transcatheter tricuspid valve implantation by femoral approach in trivalvular heart disease. Pubblicato su Am J Cardiol. 2013;112:1051-3.

Membro del EAPCI- EuroPCR Relations Committee

Membro del Gruppo Europeo di esperti in sistemi di supporto circolatorio meccanico percutaneo IMPELLA

Membro del European Bifurcation Club, gruppo di studio dedicato della EAPCI-ESC.

Coordinatore Italiano del Gruppo Europeo di studio in aterectomia direzionale EUROTA.

11. Progetti di ricerca finanziati da enti Pubblici o Privati.

CEREA-DES: National Multicenter Randomized Trial: Cortisone Eliminates Restenosis as Effectively as DES. Progetto Ricerca Finalizzata della Regione Piemonte (N° 14/2004-2005), durata 24 mesi. Coordinatore Nazionale e Principal Investigator.

EXECUTIVE: National Multicenter Randomized Trial on Excel versus Taxus in the treatment of multi-vessel disease. Coordinatore Nazionale e Principal Investigator. with a restricted gant from Abbott Vascular Italy.

Progetto di Ricerca Finalizzata della Regione Veneto: ARSENAL. Flusso informativo in Cardiologia e Cardiochirurgia. Investigatore.

CART: National Multicenter Registry. Cardial Allograft Reparative Therapy. Coordinatore Nazionale e Principal Investigator. with a restricted gant from Abbott Vascular Italy. CESC:

Volcano per FFR i TAVI: with a restricted gant from Volcano International. CESC:

FAITAVI: National Multicenter Randomized Trial on Fuctional Assessment in TAVI. Coordinatore Nazionale e Principal Investigator. with a restricted gant from Philips International and Edwards Lifescience. CESC:

12. Brevetto ed invenzioni

Brevetto industriale n TO 2004A000760, depositato in data 3 novembre 2004 presso l'Ufficio Italiano Brevetti e Marchi (UIBM) del Ministero delle Attivita' Produttive come Inventore del prodotto "Restenon", trattamento della stenosi vascolare e la prevenzione delle restenosi vascolare dopo angioplastica.

Come stabilito dallo Statuto dell'Universita' del Piemonte Orientale, gli inventori hanno ceduto i diritti di commercializzazione del prodotto all'Universita', mantenendone la paternita' scientifica ed i diritti intellettuali.

European Countries extension of the patent n 05809315.4-2123-IB 2005003271

**13. Collaborazione con giornali scientifici, redazionale e di “peer review
*Membro dell’Editorial Board di:***

European Heart Journal

Giornale Italiano di Cardiologia Interventistica

Journal of the Argentine College of Intervetional Cardiology

Seminars in Cardiovascular Medicine

Heart Blood and Vessels

Revisore di lavori per le seguenti riviste:

American Heart Journal

American Journal of Cardiology,

American Journal of Medicine,

Atherosclerosis

Cardiovascular Revascularization Medicine

Circulation,

Clinical Chemistry,

Drugs,

Eurointervention,

European Heart Journal,

Heart,

International Journal of Cardiology,

Journal of Cardiovascular Medicine,

Journal of Clinical Pharmacology,

Journal of Haemostasia and Thrombosis,

Journal of Interventional Cardiology,

Journal of the American College of Cardiology,

The Lancet.

Thrombosis and Vascular Biology,

14. Capitoli di libri

Gastaldi L, Morello M, Casalucci D, Ribichini F, et al. European consensus on standards and guidelines for global and regional ventricular function from echocardiography: Parameters to assess myocardial contractility. Echocardiography, Chapter in book, Elsevier Publisher, 1990: 315-320

Steffenino G, Bobbio M, Orzan F, Ribichini F et al. Recidiva dopo seconda angioplastica coronarica: quale scelta terapeutica?. in Librex Editori, Cardiologia 1991; Chapter in book Milano, p 337-342

Russo P, Steffenino G, Dellavalle A, Ribichini F, Uslenghi E. Criteri clinici ed angiografici per la selezione dei pazienti per la PTCA con e senza stand-by cardiocirurgico. In New Trends in PTCA. Chapter in book. Torino 1994; 21-28

Ribichini F, Steffenino G, Dellavalle A, Uslenghi E. La angioplastia primaria como tratamiento de eleccion en el infarto de miocardio de alto riesgo. Capitulo del libro: Avances en Medicina '95. Sociedad Argentina de Medicina, Buenos Aires 1995; 289-297

Ribichini F, Steffenino G, Dellavalle A, Russo P, Uslenghi E. L'impiego dello stent può estendere l'indicazione ad angioplastica coronarica nell'infarto acuto dopo trombolisi? Controversie in Cardiologia. 32° Convegno Internazionale di Cardiologia 1998, Milano 1998. Chapter in book, p 3-12

Ribichini F, Uslenghi E. Polimorfismi dell'ACE e malattia coronarica. In Ipertensione arteriosa e genetica. Editato dalla Societa Italiana dell'Ipertensione Arteriosa. Torino 1999, chapter in book, p 47-54

Editor of the web-based e-book: Trattamento della Malattia Carotidea. Prous Science, Barcelona 2008.

Pharmacology in the Catheterization Laboratory. Willey Blackwell, NJ US 2010. ISBN 978-1-4051-5704-9. Autore del capitolo " Systemic Pharmacotherapy for In-stent Restenosis.

Endovascular Surgery for Congenital and Acquired Heart Disease. Edito da Bokeria & B. G. Alekian. Moscow 2008. Autore del Capitolo 14, Vol 1: Atherosclerosis. Basis of Medical Therapy for the Intervetionalist.

Percutaneous Interventional Cardiovascular Medicine Textbook. Europa Edition, Toulouse,

France 2012. ISBN, 978-2-913628-57. Autore del capitolo: Interventions for Patients with Chronic Renal Disease.

Endovascular Surgery for Congenital and Acquired Heart Disease. Editon, Bokeria & B. G. Alekian. Moscow 2016. Autore del Capitolo 8, Vol 1: Atherosclerosis. Basis of Medical Therapy for Interventionalists

Endovascular Surgery for Congenital and Acquired Heart Disease. Editon, Bokeria & B. G. Alekian. Moscow 2016. Autore del Capitolo 14, Vol 1: Kidney Disease and Coronary Interventions.

Endovascular Surgery for Congenital and Acquired Heart Disease. Editon, Bokeria & B. G. Alekian. Moscow 2017. Autore del Capitolo 14, Vol 1: The need for emergency surgical stand-by in interventional cardiology.

15. Seminari e Conferenze presso istituzioni accademiche e relazioni su invito in Congressi, o Simposi.

1994-95

1. 68th Annual Scientific Meeting of the American Heart Association. Anaheim, USA. November 13-16 1995. Speaker.
2. XVIII Congresso nazionale del gruppo italiano di studi emodinamici e cardiologia interventistica, Vicenza 5-7 ottobre 1995. Relatore.
3. V Giornate Cardiologiche. Cuneo, 7 Ottobre 1995. Relatore invitato.
4. 17th Congress of the European Society of Cardiology. Amsterdam, 19-24 August 1995. Speaker.
5. XXVI Congress of the Italian Society of Cardiology (ANMCO). Florence, Italy. June 4-7, 1995. Speaker.
6. Jornadas de actualizacion medica. Fundacion Vida. Salta, Argentina, 20 dicembre 1994. Invited speaker. La angioplastia con stent intracoronario.
7. XXI Congresso de la Sociedad Argentina de Medicina. Buenos Aires, Argentina, 21-25 Novembre 1995. Invited speaker. La Red del tratamiento del infarto agudo.
8. Symposium New trends in PTCA. Torino, 7 Maggio 1994. Invited speaker: L'angioplastica coronarica senza stand-by cardiocirurgico

1996

9. 69th Annual Scientific Meeting of the American Heart Association. New Orleans, USA. November 10-13 1996. Speaker.

10. 30 Convegno Internazionale di Cardiologia, Centro A. de Gasperis. Milano 22-27 Settembre 1996. Relatore Invitato.

11. 18th Congress of the European Society of Cardiology. Birmingham, UK. 25-29 August 1996. Speaker.

12. XXVII Congress of the Italian Society of Cardiology (ANMCO). Florence, Italy. June 9-12, 1996. Speaker.

13. 45 Annual Scientific Session of the American College of Cardiology, Orlando, USA. March 24-27 1996. Speaker.

14. Sophia Antipolis, European Heart House, 12-13-January 1996 First joint meeting of the national working groups on interventional cardiology, speaker.

1997:

15. "ACE e ACE –inibizione: nuove acquisizioni fisiopatologiche e nuove prospettive terapeutiche". February 27, Cuneo (Italy)."Predisposizione genetica e malattia coronarica: ruolo del genotipo per l'ACE": invited faculty (speaker);

16. Seminar on Cardiovascular Genetics. Ospedale San Raffaele, Milan, Italy. 17/04 1997. Invited Speaker.

17. ANMCO "XXVIII Congresso Nazionale di Cardiologia". June 1-4, Florence (Italy): invited faculty (speaker);

18. XIX ESC Congress 1997. August 24-28, Stockholm (Sweden): invited faculty (speaker);

19. "XIX Congresso Nazionale della Società Italiana di Cardiologia Invasiva". October 9-11, Bologna (Italy): invited faculty (speaker);

20, 70th Annual Scientific Meeting of the American Heart Association. Orlando, USA. November 9-12 1997. Speaker.

21. 5th Joint Meeting of the Belgian and Dutch working groups on invasive cardiology. December 5, Brussels (Belgium);

1998:

22. 17th Annual scientific meeting of the Belgian society of cardiology. February 5-7. 1998, Brussels (Belgium); Invited Speaker. “Coronary Brachytherapy: a new alternative to prevent restenosis”.
23. Vascular and Myocardial aspects of ischemic heart disease. February 22-25, Lake Tahoe (U.S.);
24. Frontiers in Interventional Cardiology: Head to Toe Percutaneous Revascularization. February 25 – March 1, Houston (U.S.); Course.
25. Convegno Ipertensione Arteriosa e Cuore. Italian Society of Hypertension. Cuneo, Italy. 14/03 1998. Invited Speaker. Session: The Genetic of the RAS.
26. 47th Annual Scientific Session of the American College of Cardiology, Atlanta, USA. March 29, April 1 1998. Chairman of the Fireside Panel of the American College of Cardiology: Primary Angioplasty: Where, How and When.
27. Congress of the Italian Society of Cardiology (ANMCO). Florence, Italy. 7-10 June 1998. Chairman of the Session on Primary PTCA.
28. 20th Congress of the European Society of Cardiology. Vienna. Austria. 23-26/08 1998. Invited Speaker, Session: Debate, Controversies in Coronary Stenting.
29. 32° Convegno Cardiologia “A. De Gasperi”. September 21-25, Milan (Italy). “L’impiego dello stent può estendere l’indicazione all’angioplastica coronarica nell’infarto acuto dopo trombolisi?”: invited faculty (speaker);
30. 2nd International meeting on pathophysiology of stunning, hibernation and preconditioning. October 15-17, Taormina (Italy): invited faculty (speaker);
31. 5th Heart Center Course on Coronary Stenting, Rotterdam The Netherlands, December 10 1998. Invited to perform a live demonstration case of intracoronary beta brachytherapy.
32. Symposium on Molecular Cardiology. Afligem, Belgium 14/12/1998. Invited Speaker.
33. 12th Annual Scientific Sessions of the Belgian and Dutch Working Groups on Invasive Cardiology. Symposium on Intracoronary Brachytherapy. Zaventem, Belgium. 5-12-1998.
- 1999:**
34. International Workshop: The dawn of a new era in the treatment of acute myocardial infarction. January 29-30, Florence (Italy): invited faculty (speaker);

35. 5th International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”. January 31 – February 2, Geneva (Switzerland): invited faculty (speaker);
36. 48th ACC congress. March 3-10, California (U.S.): invited faculty (panelist);
37. Genetica della malattia coronarica. Società Italiana di Ipertensione, 26/03/1999, Torino, Italy. Faculty Member and speaker.
38. ANMCO “XXX Congresso Nazionale di Cardiologia”. May 30 – June 2, Florence (Italy): invited faculty (speaker); Symposium: Genetic bases of the myocardial infarction in the young. Invited speaker.
39. 21th Congress of the European Society of Cardiology. Invited Speaker, Session: The Great Debate, Strategies of reperfusion in Acute Myocardial Infarction. Barcelona, Spain, August 28, September 1 1999.
40. Evidence-Based Conference of the American Heart Association for the Preparation of the Guidelines for CPR 2000. Faculty and Invited Speaker. Dallas September 25-29 1999
41. “XX Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 23-25, Palermo (Italy): invited faculty (speaker);
42. Intravascular radiotherapy. December 17, Bergamo (Italy): invited faculty (moderator);

2000:

43. International guidelines 2000 conference on CPR and ECC. February 6-8, Dallas (U.S.). “Acute Coronary Syndromes”: invited faculty (panelist);
44. 49th ACC congress. March 12-15, California (U.S.): invited faculty (panelist);
45. “XXI Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 23-25, Palermo (Italy): invited faculty (speaker): Analisi Critica dei Trials con Inibitori delle Glicoproteine.
46. Simposio de Instruccion en Resucitacion para America Latina de la American Heart Association. Montevideo, Uruguay Dicembre 2000, invited speaker.
47. Training Programme on Endovascular Radiation Therapy for Restenosis Prevention. European Society of Cardiology, Sophia Antipolis, 26-28 ottobre 2000, Invited speaker.

48. XXII Congress of the European Society of Cardiology, invited speaker, Hotline Sessions. Amsterdam 26-30 August 2000: The Genetic of In-stent Restenosis. Results of the BetACE Trial
49. Washington, Armed Force Institute of Pathology (AFIP), Maggio 2000. Invited speaker: The angiographic presentation of restenosis. Clinical and prognostic implications.
50. Faculty e relatore invitato al DANAMI-2 meeting and meeting of the Scandinavian Society of Cardiology. Arhus, Danimarca, 5-6 Maggio 2000.
51. Stanford University, California. Invited speaker. March 2000. Relazione: The role of ACE and ACE-inhibition in vascular repair after percutaneous injury.
52. Scientific Sessions of the American College of Cardiology, New Orleans, March 2000. Presenter.

2001:

53. 2nd International summit on acute cardiovascular care. January 31 – February 2, Aosta (Italy): invited faculty (speaker);
54. “XVI Giornate Cardiologiche Torinesi”. April 6-7, Turin (Italy). “Ruolo della farmacoterapia nella restenosi”: invited faculty (speaker);
55. Endocoronary Biomechanics and restenosis. April 6, Marseille (France). “Polyphormism I.D. ACE and restenosis: invited faculty (speaker);
56. XVI Annual Meeting of the American Society of Hypertension, San Francisco 15-19 Maggio 2001. Presenter.
57. GISE - “Appropriatezza fattibilità e costo/utilità delle procedure diagnostiche e dei trattamenti nelle sindromi coronariche acute”. May 4, Bologna (Italy): invited faculty (speaker);
58. “Riunioni scientifiche regionali – SIC”. May 19, Genova (Italy). “L’analisi decisionale nella cardiopatia ischemica”: invited faculty (speaker);
59. International meeting on vascular interventions. June 18-23, Positano (Italy): invited faculty (speaker): “Primary angioplasty versus systemic thrombolysis”.
60. Forum question and answer dell’ANMCO sui trattamenti delle sindromi coronariche acute. Bari, settembre 2001. Invited speaker.
61. ESC Congress 2001. September 1 - September 5, Stockholm (Sweden): invited faculty (speaker);
62. “II Congresso nazionale della società italiana di anatomia patologica e citopatologia diagnostica”. September 23-27, Turin (Italy).
63. Second Panafrican Course on Interventional Cardiology. October 5-6, Monastir (Tunisia). “Direct PCI is the best treatment”: invited faculty (speaker);
64. First International PCI-AMI Meeting in Zurich. October 5-6, Zurich (Switzerland). “Can We define a common initial treatment strategy combining lytics and platelet inhibitors for all patients with AMI”: invited faculty (speaker);
65. Symposium on NSTEMI. The medical approach. Meeting of the Italian Society of Cardiology. Novara 13 ottobre 2001, relatore invitato.
66. “Riunioni scientifiche regionali – SIC”. October 13, Genova (Italy). “L’analisi decisionale nella cardiopatia ischemica”: invited faculty (speaker);

67. “XXII Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 24-27, Cernobbio (Italy): invited faculty (speaker);

68. Congress of the Italian Society of Cardiology (SIC). Interventional procedures with use of flow and pressure coronary wires transmitted to as live cases from the catheterization Laboratory of the Ospedale Maggiore della Carita’ di Novara. Novara, 13 December 2001. Invited operator.

2002:

69. 8th International LDDR and Molecular Biology Course. Ginevra Switzerland 31/01-02/02 2002. Faculty Member as invited speaker.

69. ANMCO “XXXIII Congresso Nazionale di Cardiologia”. May 18-22, Florence (Italy): invited faculty (speaker);

70. EuroPCR. May 21-24, Paris (France): invited faculty (speaker). Embolic Protection Systems in Acute Myocardial Infarction” Acute Coronary Syndromes. May 22, Paris (France). “Embolic Protection”: invited faculty (speaker);

71. 11th Interventional Cardiology Symposium. June 5-7, Montreal (Canada): invited faculty (speaker): primary Angioplasty versus Trombolysis.

72. ESC Congress 2004. August 31 - September 4, Berlin (Germany): invited faculty (speaker and Chairman);

73. ESC Antithrombotic, Fibrinolytic and interventional treatment of unstable angina and MI. October 17-19, Riga (Latvia). “Genetic risk factors for restenosis after coronary interventions”: invited faculty (speaker/moderator);

74. Third Panafrican Course on Interventional cardiology. October 3-5, Monastir (Tunisia. “Physiological assessment of vascular lesions. When and how?”: invited faculty (speaker);

75. “6° Corso di intervenzionistica cardiologica in Italia”. October 7-9, Novara (Italy). Co-director and live case operator.

76. “XXIII Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 23-26, Verona (Italy): invited faculty (speaker); Istologia della aterosclerosi e della restenosi.

77. SIC “Aggiornamenti sul trattamento della patologia cardiovascolari”. November 8-9, Turin (Italy). “Gli inibitori delle glicoproteine IIb/IIIa.”: invited faculty (speaker);

2003:

78. 9th International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”. January 23-25, Geneva (Switzerland): invited faculty (speaker);
79. Joint interventional meeting (JIM). February 13-15, Rome (Italy). “Overview of reperfusion treatment of AMI”: invited faculty (speaker);
80. “XVI Giornate Cardiologiche Torinesi”. April 11-12, Turin (Italy). “Gli stent medicati devono essere utilizzati in tutti i pazienti?”, “Ruolo degli ACE-inibitori”: invited faculty (speaker);
81. C-reactive protein, from pathophysiology to guidelines. July 7, Rome (Italy). “Steroids and restenosis”: invited faculty (speaker);
82. ESC Congress 2003. August 30 - September 3, Vienna (Austria): invited faculty (speaker);
83. CD rom invasive cardiology 2003, Gargonza, 3-5 ottobre 2004, relatore invitato.
84. SCIMAB Boston Scientific medical Advisory Board. November 6-7, Portofino (Italy). “Indicazioni cliniche dei DES: must have and nice to have”: invited faculty (speaker);
85. Transcatheter Cardiovascular Therapeutics (TCT), September 15-19, Washington DC (U.S): invited faculty (speaker); The Inflammation Summit.
86. “7° Corso di intervenzionistica cardiologica in Italia”. October 3, Novara (Italy). Co-director and live case operator.
87. “Controversie nel trattamento della cardiopatia valvolare e dello scompenso cardiaco avanzato”. October 10-11, Turin (Italy): invited faculty (speaker);
88. “XXIV Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 15-18, Genova (Italy): invited faculty (speaker);
89. Fourth Pan African Course of Interventional Cardiology. Monastir, Tunis October 3-5 2003. Invited live transmission from Novara.

2004:

90. 10th International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”. January 29-31, Geneva (Switzerland): invited faculty (speaker);
91. Joint interventional meeting (JIM). February 12-14, Rome (Italy): invited faculty (chairman);
92. 3rd European conference on management of coronary heart disease. April 2-4, Nice (France). Invited Speaker.
93. XV Giornate Cardiologiche Torinesi, Torino 20-23 Aprile, Relatore invitato.
94. “Corso di cardiologia ad impronta cardiocirurgica”. April 15, Novara (Italy): invited faculty (speaker);
95. CD Rom Invasive cardiology. April 16-18, Mogliano Veneto, Treviso (Italy) Invited Speaker: Complex PCI in Multi-vessel disease
96. Nuove Frontiere in Cardiologia Interventistica. Sesto San Giovanni, Milano, 4-5 giugno 2004. Relatore invitato.
97. EuroPCR. May 25-28, Paris (France): invited faculty (speaker);
98. “The 5th Moscow’s international course on endovascular surgery of congenital and acquired heart diseases, coronary and vascular pathology. June 8-10, Moscow (Russia). “Acute coronary syndrome:using of dexamet-elutingstents – review of STRIDE and EMPEROR Trials.: invited faculty (speaker); and live case operator.
99. X SOLACI (Società Latino Americana de Cardiologia Invasiva) Devices Symposium. August 5, Buenos Aires, Argentina. “DEXAMET: a steroid-eluting stent and DESIRE study”: invited faculty (speaker);
100. ESC Congress 2004. August 28 - September 1, Munich (Germany): invited faculty (speaker);
101. Transcatheter Cardiovascular Therapeutics (TCT), September 27 - October 1, Washington DC (U.S): invited faculty (speaker);
- 102 “XXV Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 6-9, Napoli (Italy): invited faculty (speaker);
103. Riunione Regionale Scientifica della SIC. “Il cardiologo sul pianeta diabete”. October 16, Turin (Italy). “Alternative agli stent medicati?”: invited faculty (speaker);
104. “65° Congresso Nazionale della Società Italiana di Cardiologia”. December 11-15, Rome (Italy): invited faculty (speaker);

2005:

105. 11th International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”. February 3-5, Geneva (Switzerland): invited faculty (speaker);

106. Joint interventional meeting (JIM). February 17-19, Rome (Italy). “Overview of reperfusion treatment of AMI”: invited faculty (speaker);

107. 20th Annual Interventional Cardiology International Symposium. March 20-25, Colorado (U.S.). “Remaining space for oral drug in multi-vessel treatment”: invited faculty (speaker);

108. 3rd International summit on acute cardiovascular care. May 12-14, Venice (Italy): invited faculty (speaker);

109. EuroPCR. May 24-27, Paris (France): invited faculty (speaker);

110. “XXVI Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 15-18, Genova (Italy): invited faculty (speaker);

111. Sixth Panafrican Course on Interventional cardiology. September 29 - October 1, Monastir (Tunisia). “Physiological assessment of vascular lesions. When and how?”. Invited faculty (speaker);

112. XI CECI Interventional cardiology meeting- Otamendi Hospital LIVE demonstration course. October 29-30, Buenos Aires (Argentina): invited faculty (speaker); “Oral Prednisone and Atherosclerotic Disease”.

113. Transcatheter Cardiovascular Therapeutics (TCT), October 16-21, Washington DC (U.S.): invited faculty (speaker);

114. Prevention of Restenosis. October 18, Washington DC (U.S.). “Role of inflammation in restenosis, and Utility of Anti-Inflammatory Compounds in Drug-Eluting Stents” : invited faculty (speaker);

115. “Statine: una pillola per ogni stagione?”. November 19, Verona (Italy). “Statine e cuore: non e1 mai troppo presto: invited faculty (speaker);

116. “Update sulle sindromi coronariche acute”. December 17, Ascoli Piceno (Italy). “Istologia e fisiopatologia delle placche aterosclerotiche nelle sindromi coronariche acute”: invited faculty (speaker);

2006:

117. 12th International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”. February 2-4, Geneva (Switzerland): invited faculty (speaker);
118. Joint interventional meeting (JIM). February 16-18, Rome (Italy): invited faculty (speaker);
119. TEP 2006 “Terapéutica Endovascular Percutanéa”. March 27-29, Buenos Aires (Argentina): invited faculty (speaker): “The Evolution of Anti-coagulant and Anti-platelet therapy in Interventional Cardiology”
120. Workshop TEAM: “Estrategias de reperfusión óptimas y modelos de organización asistencial en pacientes con infarto agudo de miocardio”, June 22-23, Vigo (Spain): invited faculty (moderator);
121. SIC –Linee guida interventistica coronarica percutanea. July 8, Verona (Italy): invited faculty (speaker);
122. “Una rete può salvare una vita: utilità di una rete territoriale per il trattamento dell’infarto acuto del miocardio”. September 23, Verona (Italy): invited faculty (speaker);
123. “Il trittico del cuore”. September 22-24, Verona (Italy): invited faculty (speaker);
124. Congresso della Società Russa di Cardiologia Interentistica. Invited speaker and live case operator. Novosibirsk, Siberia, Russia, 29-30 Settembre 2006.
125. “XXVII Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 3-6, Genova (Italy): invited faculty (speaker);
126. Transcatheter Cardiovascular Therapeutics (TCT), October 22-27, Washington DC (U.S): invited faculty (speaker);
127. “VIII giornata di cardiologia Interventistica Miranese”. November 18, Venice (Italy). “Possibilità e limiti della rivascolarizzazione coronarica percutanea”: invited faculty (speaker);
128. “C’era una volta l’angina”. November 25, Verona (Italy). “Rivascolarizzazione, solo a pochi?": invited faculty (speaker) ;
129. Abbott Crossroads – Complex lesions: Risk assessment and management. Brussels, December 1st. Invited Lecturer: “The treatment of coronary bifurcations”.

2007:

130. High tech Marseille. January 24-26, Marseille (France): invited faculty (speaker);
131. 14th International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”. February 1-3, Geneva (Switzerland): invited faculty (speaker);
132. Joint interventional meeting (JIM). February 15-17, Rome (Italy): invited faculty (speaker);
133. TEP 2007 “Terapèutica Endovascolar Percutanéa”. April 23-25, Buenos Aires (Argentina): invited faculty (speaker);
134. “Con il cervello e con il cuore”. May 19, Verona (Italy): invited faculty (speaker and chairman); La terapia anti-coagulante nelle sindromi coronariche e neurologiche acute.
135. EuroPCR. May 22-25, Barcelona (Spain): invited faculty (speaker);
136. The 9th Moscow’s international course on endovascular surgery of congenital and acquired heart diseases, coronary and vascular pathology. June 4-6, Moscow (Russia): invited faculty (speaker) and live case operator.
137. 16th Interventional Cardiology Symposium. June 17-19, Montreal (Canada): invited faculty (speaker); peripheral interventions for cardiologists
138. 4th International summit on acute cardiovascular care. June 19-21, Verona (Italy): invited faculty (speaker);
139. Symposium “A step beyond in DES”. October 2-5, GISE Congress, Genova (Italy): invited faculty (speaker);
140. Critical issues in interventional cardiology. September 20, Munich (Germany): invited faculty (workshop leader);
141. V Tyrolean Meeting, September 21-22. Bolzano (Italy): invited faculty (speaker);
142. “IX giornata di cardiologia Interventistica Miranese”. November 17, Venice (Italy): invited faculty (speaker); I sistemi di supporto emodinamico nella PCI complessa.
143. “Attualità e prospettive future del trattamento chirurgico ed endovascolare nei pazienti vasculopatici”. November 22, Verona (Italy): invited faculty (speaker)

2008:

144. IV Corso di specializzazione in emodinamica e cardiologia interventistica. February 5, Milano (Italy): invited faculty (speaker);
145. 15th International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”. February 7-9, Geneva (Switzerland): invited faculty (speaker);
146. Joint interventional meeting (JIM), February 14-16, Rome (Italy): invited faculty (speaker);
147. III International course in prevention and treatment of complications in percutaneous interventional cardiology. February 28-29, Barcelona (Spain): invited faculty (speaker);
148. “III Convegno Cuneese di medicina nucleare”, April 5, Cuneo (Italy): La rivascularizzazione miocardica nel paziente con insufficienza renale terminale.
149. “Incontri di Cardiologia del Triveneto: il trattamento della cardiopatia ischemica tra tecnologia, organizzazione sanitaria ed evidence-based medicine”, April 19, Verona (Italy): invited faculty (speaker);
150. EuroPCR, May 13-16, Barcelona (Spain): invited faculty (speaker);
151. Modern strategies in interventional cardiology, June 26-27, Aarhus (Denmark). Invited Lecturer: From thrombolysis to PCI.
- 152 “Cardiologia oggi: esperienze a confronto”, September 20, Vercelli (Italy): invited faculty (speaker); Lettura Magistrale: storia della riperfusione miocardica.
153. Transcatheter Cardiovascular Therapeutics (TCT), October 12-17, Washington DC (U.S): invited faculty (speaker);
154. “Il Paziente diabetico con cardiopatia ischemica”, October 25, Verona (Italy): invited faculty (speaker); La rivascularizzazione del paziente diabetico.
155. Convegno Sda Bocconi “Tecnologie sanitarie e modelli di acquisizione pubblici per la salute”, November 10, Milan (Italy): invited faculty (speaker);
156. “X giornata di cardiologia Interventistica Miranese”. November 15, Venice (Italy): invited faculty (speaker);

2009:

157. 16th International LDD&R “Local Drug Delivery meeting and cardiovascular course on revascularization & molecular strategies”, February 5-7, Geneva (Switzerland): invited faculty (speaker);
158. Joint interventional meeting (JIM), February 12-14, Rome (Italy): invited faculty (speaker);
159. “ Dalla disfunzione ventricolare sinistra asintomatica allo scompenso cardiaco refrattario”. March 21, Cuneo (Italy): invited faculty (speaker);
160. “Percorso diagnostico-terapeutici nella sindrome coronarica acuta”. April 23, Verona (Italy): invited faculty (speaker);
161. OCT, IVUS, FFR. When, where and how. Interactive course on intravascular imaging with minimally invasive approach. May 28-29, Bergamo (Italy): invited faculty (speaker);
162. The 10th Moscow’s international course on endovascular surgery of congenital and acquired heart diseases, coronary and vascular pathology. June 1-3, Moscow (Russia): invited faculty (speaker and live case operator);
163. Italian forum on primary PCI. June 24, Milan (Italy): invited faculty (speaker);
164. ESC/EACTS Task Force Meeting on Myocardial Revascularization. July 6-7, Sophia Antipolis (France): member.
165. “I^a Conferenza nazionale sulla trombolisi nell’ictus ischemico”. September 18-19, Verona (Italy): invited faculty (speaker);
155. Transcatheter Cardiovascular Therapeutics (TCT). September 21-25, San Francisco (U.S): invited faculty (speaker);
156. “L’imaging nella diagnostica del cuore”. October 3, Verona (Italy) Speaker.
157. 5th International summit on acute cardiovascular care. October 8-9, Verona (Italy): invited faculty (speaker);
158. “XXX Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 20-23, Bologna (Italy): invited faculty (speaker);
159. “Meeting: “Nature of Superiority”. November 11, Moscow (Russia) invited faculty (Invited Lecture);
160. “3° Corso di Interventistica Vascolare”. November 13-14, Palermo (Italy): invited faculty (speaker); La malattia vascolare pluridistrettuale.
161. Working Group on Stent Evaluation and adoption. Munich December 9 2009. Chairman.

162. “70° Congresso Nazionale della Società Italiana di Cardiologia”. December 12-15, Rome (Italy): invited faculty (speaker);

2010:

163. Joint interventional meeting (JIM), February 11-13, Rome (Italy): invited faculty (speaker);

164. The 6th Belgrade Summit of Interventional Cardiologist plus. April 10-13, Belgrade (Serbia): invited faculty (speaker);

165. VII European Congress: Healthy and active ageing for all Europeans. April 14-17, Bologna (Italy): invited faculty (speaker); TAVI: an emerging therapeutic option for the elderly patient with aortic stenosis.

166. IV International course in prevention and treatment of complications in percutaneous interventional cardiology. April 22-23, Barcelona (Spain): invited faculty (speaker);

167. “Stenting Carotideo: Indicazioni e risultati”. April 30, Rome (Italy);

168. EuroPCR, May 25-28, Paris (France): invited faculty (speaker);

169. The 11th Moscow’s international course on endovascular surgery of congenital and acquired heart diseases, coronary and vascular pathology, June 6-9, Moscow (Russia): invited faculty (speaker and live case operator);

170. 19th Interventional Cardiology Symposium. June 17-19, Montreal (Canada): invited faculty (speaker); Immunosuppression to avoid stent Restenosis: The CEREAS-DES study.

171. XVI SOLACI 2010. August 11-13, Buenos Aires (Argentina): invited faculty (speaker); The FRIENDS collaborative study: Combine Carotid and Coronary Interventions. Main Lecture: Update on Drug Eluting Stents.

172. ESC Congress 2010. August 28 - September 1, Stockholm (Sweden): invited faculty (speaker); Main Lecture: Presentation of the ESC Guidelines for Myocardial Revascularization.

173. “ Iperglicemia, QTc, Iperprolattinemia e disturbi del movimento: istruzioni per l’uso degli antipsicotici”. September 17, Verona (Italy): invited faculty (speaker);

174. Transcatheter Cardiovascular Therapeutics (TCT). September 21-25, Washington DC (U.S): invited faculty (speaker);

175. XI Athens Interventional Cardiovascular Therapeutics. October 8-9, Athens (Greece): invited faculty (speaker); Immunosuppression to avoid stent Restenosis: The CEREAS-DES study.

176. “ La terapia con inibitori della glicoproteina IIb/IIIa nelle sindromi coronariche acute. Dalle linee guida alla pratica clinica”. October 16, Verona (Italy): invited faculty (speaker);

177. “31° Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 19-22, Genova (Italy): invited faculty (speaker);

178. “4° Corso di Interventistica Vascolare”. November 5-6, Palermo (Italy): invited faculty (speaker);

179. “Realizzazione, condivisione ed implementazione della scheda integrata di terapia presso la divisione clinicizzata di cardiologia dell’azienda ospedaliera di Verona”. February – December 2010, Verona (Italy);

180. “71° Congresso Nazionale della Società Italiana di Cardiologia”. December 11-13, Rome (Italy): invited faculty (speaker);

181. Asian Medical Advisory Board of Abbott in Polymers and new drug eluting stents. Chairman. Singapore, September 8-10 2010.

2011

182 Joint interventional meeting (JIM). February 10-12, Rome (Italy): invited faculty (speaker);

183. VII Corso di specializzazione in emodinamica e cardiologia interventistica, March 1, Rozzano, Milano (Italy): invited faculty (speaker): La rivascularizzazione miocardica nel paziente con angina stabile.

184. “Incontro Regionale di Cardiologia Interventistica”. March 26, Nuoro (Italy): invited faculty (speaker). Review on Drug Eluting Stent Thrombosis.

185. e-VACS 2011. April 14-15, Venice (Italy): invited faculty (speaker); Analysis of recent TAVI trials.

186. “Interventistica Interregionale GISE”. May 6, Padova (Italy): invited faculty (speaker);

187. EuroPCR. May 17-20, Paris (France): invited faculty (speaker), and member of the Scientific Committee.

188. Cardiovascular Therapeutics India (CVT). August 20-21, New Delhi (India): invited faculty (speaker); Drug-eluting balloons, rational, indications and results. Peripheral interventions for the Cardiologists (speaker).

189. ESC Congress 2011. August 27-31, Paris (France): invited faculty (speaker);

190. “32° Congresso Nazionale della Società Italiana di Cardiologia Invasiva”. October 11-14, Genova (Italy): invited faculty (speaker);

191. “Meeting di Cardiologia: Il rischio, la malattia, la terapia. October 21-22, Olbia (Italy): invited faculty (speaker);

192. “5° Corso di Interventistica Vascolare”. November 3-5, Palermo (Italy). “Il paziente con patologia carotidea e coronarica concomitante: quale approccio quale terapia”: invited faculty (speaker);

193. Transcatheter Cardiovascular Therapeutics (TCT). November 7-11, San Francisco (U.S): invited faculty (speaker);

194. “XIII giornata di cardiologia Interventistica Miranese”. November 26, Venice (Italy): invited faculty (speaker);

195. “72° Congresso Nazionale della Società Italiana di Cardiologia”. December 10-12, Rome (Italy): invited faculty (speaker);

2012:

196. “1ª Reunião do grupo VAP/APIC”. January 20, Coimbra (Portugal): invited faculty (speaker);

197. High tech Marseille, January 25-27, Marseille (France): invited faculty (speaker);

198. Joint interventional meeting (JIM). February 9-11, Rome (Italy): invited faculty (moderator);

199. TAVI Expert Summit. February 28, Milan (Italy); Chairman

200. Medtronic CV International Technology Exchange Programme. March 8-10, Prague - Czech Republic: invited faculty (speaker) and Course Co-Director.

201. V International course in prevention and treatment of complications in percutaneous interventional cardiology. April 19-20, Barcelona (Spain): invited faculty (speaker);

202. “Interventistica Interregionale GISE”. May 4, Bologna (Italy): invited faculty (speaker): La rivascularizzazione del paziente, multivasale: chirurgia vs angioplastica.

203. “Congresso Regionale ANMCO Veneto”. May 12, Legnaro (Italy): invited faculty (speaker);

204. EuroPCR, May 15-18, Paris (France): invited faculty (speaker) and member of the Scientific Committee.

205. TCT Russia: XIV Moscow’s International Course on Endovascular Therapies. May 28-30, Moscow (Russia): invited faculty (speaker). Main Lecture: DES Restenosis. Live case operator.

206. 7th International Interventional Forum. June 7-8, Garda (Italy): invited faculty (speaker); The use of IVUS in interventional cardiology.

207. Meet the Masters. June 14-15, Villepinte (France): invited faculty (speaker); All you need to know to perform peripheral vascular interventions.

208. Medical Advisory Forum: Vascular Reparative Therapy. June 14, Brussels (Belgium): member;

209. “Simpósio Satélite Medtronic: Avanços e novas tecnologias na intervenção”. June 21, Salvador (Brasil). Congresso della Società Brasiliana di Cardiologia Invasiva. Invited faculty (speaker);

210. PCR London Valves. September 30 – October 2, London (United Kingdom): invited faculty (speaker);

211. “33° Congresso Nazionale della Società Italiana di Cardiologia Invasiva”, October 3-5, Genova (Italy): invited faculty (speaker);

212. “Seminari Endocrino Metabolici”. November 19, Verona (Italy): invited faculty (speaker): La Rivascolarizzazione miocardica nel paziente diabetico.

213. THV Proctors meeting. November 23, Nyon (Switzerland); Moderator.

214. “32° Congrès national de cardiologie et de chirurgie cardiovasculaire”. November 28 – December 1, Tunis (Tunisia): invited faculty (speaker). TAVI Update avec self auto-expandable protheses.

215. Medical Advisory Board: Bioresorbable Vascular Scaffolds. December 6, Brussels (Belgium): member.

216. “73° Congresso Nazionale della Società Italiana di Cardiologia”, December 15-17, Rome (Italy): invited faculty (speaker): La Rivascolarizzazione Miocardica: Linee Guida a Confronto.

2013:

217. High Tech Marseille, February 1, Marseille (France): invited faculty. Ma meilleure astuce avec une CoreValve (speaker);

218. Joint interventional meeting (JIM), February 14-16, Rome (Italy); Symposium on physiologic coronary assessment and imaging. Chairman.

219. “Tre anni di TAVI: (Trans-Catheter Aortic valve Implantation)”. April 5, Verona (Italy): invited faculty (speaker); Tre anni di TAVI a Verona.

220. Abbott VRT Round Table. May 14th 2013, Catania (Italy): invited faculty (speaker); BVS: From stenting to vascular reparative therapy (VRT).
221. EuroPCR, May 21-24, Paris (France): invited faculty and member of the Scientific Committee. (Speaker).
222. Congresso Nazionale della Società Italiana di Nefrologia. Firenze, 26 Settembre 2013. Il trattamento invasivo delle SCA nel paziente con insufficienza renale cronica. Invited speaker.
223. 40 anni di Cardiologia in Trentino. Settembre 28 2013: La stenosi aortica. Lettura Magistrale: “La TAVI domani: cosa faremmo tra 5 anni e come”
224. “La valutazione fisiologica delle stenosi coronariche con FFR e o iFR: Introduzione all’approccio ibrido. Istituto Clinico Sant’Ambrogio-IRCS. October 1st, Milan (Italy): invited speaker: : il concetto di “instant wave-free” ratio.
225. ICCAD 2013: International Congress on Coronary Artery Disease. Florence, October 14th 2013. Invited speaker: Interventional Cardiovascular Medicine. A New Speciality on the Horizon? How to Set up an Interventional Medicine Practice.
226. “Casi Clinici delle Cardiologie del Veneto”. October 18, San Bonifacio (Italy): invited faculty (speaker); Il futuro della TAVI.
227. 50 Congresso della Società Italiana di Diabetologia. Riccione, 23 Ottobre 2013. Quali approcci per la rivascolarizzazione coronarica oggi. Invited speaker.
228. Transcatheter Cardiovascular Therapeutics (TCT), October 28 – November 1, San Francisco (U.S): invited faculty (speaker); Best Challenging case award winning: Tricuspid valve in valve treatment.
229. Emergenze in Geriatria. Verona 20 Novembre 2013. Diagnostica invasiva e rivascolarizzazione delle Sindromi coronariche acute nell’anziano. Relatore
230. Veneto Cardiovascular Workshop. 3 Dicembre 2013, Mestre. Invited Speaker: La Denervazione Renale in Veneto.
231. International BVS Forum. Catania 4-6 December 2013. Invited Speaker: The Basic of Bioresorbable Scaffolding. And BVS in Cardiac Heart Transplantation.
232. International Advisory Board, Boston Scientific. New York December 12-14 2013. Faculty.

2014:

233. Medtronic – Innovation Expert Forum: “Interventional Pudendology, A New Sub-Specialty?”. January 17, Cardiff (Wales): invited faculty (speaker);

234. THV training: “Edwards SAPIEN 3™ Valve Certification training Programme. January 20, Milan (Italy).

235. Europe and Central Asia (ECA) Advisory Board Meeting. February 6-7, Madrid (Spain): invited faculty (speaker);

236. Medtronic -Prague Therapy and Technology Exchange Programme. February 19-21, Prague - Czech Republic: Course Co-director and invited faculty (speaker);

237. “Management in Chirurgia Vascolare: La presa in carico clinica e gestionale del paziente”. March 6 – April 7, Verona (Italy): invited faculty (speaker); Il trattamento della coronaropatia nel malato con vasculopatia periferica.

238. Abbott Crossroads - Percutaneous Mitral valve Repair Programme. March 26-27, 2014. Bruxelles.

239. “Aprroccio integrato anatomico-funzionale alla cardiopatia ischemica”. April 9, Venice (Italy): invited faculty (speaker); Update on renal denervation.

240. Advances in Coronary Physiology. April 29, London (United Kingdom): Invited professor at the Imperial College of London. Lecture. FFR and IFR in my clinical practice.

241. Venice Interventional Cardiology: Focus on Heart and Brain. May 15-17, Venice (Italy): invited faculty (speaker): The acute coronary and neurologic syndrome. A new medical entity.

242. EuroPCR, May 20-23, Paris (France): invited faculty (speaker) and member of the Scientific Committee. The 2014 Great Debate: Primary PCI in Acute myocardial infarction: An emergency! Speaker.

243. “ Congreso de la Sociedad Espaniola de Cardiologia. XXV Curso de intervencionismo cardíaco percutáneo para residentes en cardiología”. June 11-13, Cordoba (Spain): invited faculty (speaker): rational of the VRT in ACS.

244. “BVS: una nuova opzione terapeutica per il trattamento della Sindromi Coronariche Acute?”. June 25, Padua (Italy): invited faculty (speaker);

245. PCR London Valves, London 28-30 September 2014. Invited Speaker: Roatablator and TAVI. Emergency valve-in valve. Percutaneous treatment of dual volume overload. Speaker.

246. Seminario Cardiologico dell’Università di Foggia. BVS: una nuova opzione per il trattamento delle CAV. Foggia, 1 Ottobre 2014. Lettura Magistrale.

247. Congresso Nazionale della Società di Cardiologia Invasiva (GISE). Genova, 16-16 Ottobre 2014. Invited Speaker. Do we need cerebral protection for TAVI?

248. ESC Meeting on Acute Cardiovascular Care 2014. October 18-20, Geneva. Invited Speaker: Safety of New Drug Eluting Stents.
249. GISE Toscana-Lombardia –Veneto. Interventistica Complessa Coronarica e Strutturale. Mestre 14-15 Novembre 2014. Faculty, Invited Speaker: Quale correlazione tra IVUS ed FFR?
250. Seminari Piastrine, trombosi ed emostasi, Verona 21 Novembre. Speaker: La prevenzione della trombosi coronarica nella cardiologia interventistica.
251. XVI Giornata Cardiologica Miranese. Main Lecture: La PCI nel paziente Multivasale. Mirano 22 Novembre 2014.
252. Functional Measurement of Coronary Lesions: State of the Art. Invited speaker: La FFR in Veneto. Milano, Dicembre 3 2014.
253. Time in Brain, Verona 6 dicembre 2014. Chairman nella sessione Left atrial appendage closure.
254. Mediterranean Bioresorbable Scaffold Meeting. 19-20 Dicembre 2014, Agrigento. Invited speaker: Presupposti teorici ed evidenze della VRT.

2015

255. San Diego, January 23rd. SORIN Aortic Advisory Board on cardiac valves.
256. VI European and EMICS Technical Exchange Interventional Meeting. Rome 25-27 February April 2015. Course Director and speaker.
257. Verona, 2 Aprile. Scuola Medica Ospedaliera XXV CORSO SUPERIORE DI GERIATRIA La fragilità dell'anziano cardiopatico
258. First Latin America Technical Exchange Interventional Meeting Montevideo 8-10 April 2015. Course Director and speaker.
259. Napoli 16-18 Aprile XVII Congresso Nazionale della SIEC. Controversie sulla TAVI: La TAVI NON è una procedura soprautilizzata.
260. Nice ESC 23-24 April. The European Heart House. Coronary Physiology in the Catheterization Laboratory 9th Edition. Resting measures Pd/Pa and iFR.
270. Rovereto 15 Maggio. I meeting neuro-cardiologico trentino. Risultati a medio e lungo termine nella chiusura percutanea del PFO.
271. EuroPCR, May 18-22, Paris (France): invited faculty (speaker) and member of the Scientific Committee. Chairman of live Cases sessions and Director How-to-sessions for vascular access. Speaker.
272. TCT Russia: XVI Moscow's International Course on Endovascular Therapies. June 18-20, Moscow (Russia): invited faculty (speaker). Main Lecture: Reflections from a pioneer of primary PCI. Live case operator.
273. Invited Professor at Oxford University Cardiology Live 2015. Main Lecture on Stent Thrombosis. September 14-15th 2015.
274. Emergent International Course Symposium (EMICS) 2015. Course Co-director and speaker. Istanbul, September 23-25 2015.
275. Transcatheter Cardiovascular Therapeutics (TCT), October 10-14, 2015. San Francisco (U.S): invited faculty (speaker).
276. Congresso Nazionale della Società di Cardiologia Invasiva (GISE). Genova, 27-30 Ottobre 2015. Invited Speaker and chariman. Patients selection for TAVI
277. Course Director and live case cases performer at the Volcano course on FFR and iFR, Moscow November 17th 2015

278. XVII Giornata Cardiologica Miranese. Main Lecture: La fragilità del paziente anziano cardiocirurgico. Mirano 28 Novembre 2015.

279. Invited speaker on Coronary Bifurcations. National Congress of the Hellenic Society of Cardiology, Athens, December 12-13 2015.

2016

280 5th Rotablation Meeting and 1st Scientific Meeting of the EUROTACLUB. Worclaw 15-15 January 2016. Chairman and speaker: Rotablation in Left Main Disease, and Rotablation in Lesions with Dissections.

281. European Society Cardiology. Subject: Professor Flavio RIBICHINI attended the ESC Stroke Task Force Meeting held on 25 January 2016 at the ESC Offices in Brussels, Belgium

282 6th International Therapy and Technology Exchange Physician Program.-Medtronic. Wednesday 24 February—Friday ,26 February 2016. Hilton Prague Old Town ,Czech Republic, Program Co Chair: Flavio Ribichini, MD.

283 EMC Main issues of endovascular treatment of cardiovascular diseases. March 30, 2016.- venue Azimut Olimpic Hotel, Olympiyskiy avenue 18/1. MOSCOW. Endovascular surgery for cronic occlusions of coronary arteries. Flavio Ribichini (Italy) Coronary stent synerg—the sresults of clinical trials..Flavio Ribichini (Italy)
Relational atherectomy and intravascular ultrasound examination. Flavio Ribichini (Italy)

284 PONENTE en el VII curso internacional sobre prevencion y tratamiento de las complicaciones en cardiologia intervencionista percutanea.- Celebrado en Barcelona los dias 7 y 8 de abril 2016.

285. VII Curso Internacional sobre Prevencion y Tratamiento de las complicaciones en cardiologia intervencionista percutanea. Flavio Luciano Ribichini, asistio al curso de referencia celebrado en Barcelona los dias 7 y 8 de abril de 2016

286. MEDTRONIC. European Advisory Board..Parigi 28—29 aprile 2016. Prof. Flavio Luciano Ribichini.. Divisione Emodinamica Ospedale Civile Maggiore Borgo Trento. Verona.

287. Invited SPEAKER at the Venice International Cardiology Focus on Heart y Brain. Venice , May 5-7 2016.

288. Advances in Coronary Physiology -6-7June 2016.. ETC Venues Marble Arch. Garfield House 86 Edgware Rd. London W2 2EA. Faculty and Invited Lectures Prof. Flavio Ribichini.

289. Certificate of Attendance... Has participated as faculty in Educational activity titled TCT RUSSIA...XVIII Moscow International Course on Endovascular Therapies. 2—4 June 2016 Moscow, Russia.

290. BVS Opinioni a Confronto Monselice 24 Giugno 2016. Chairman. Absorb.

291. A Journey Across the Aortic Valve Surgery, Transcatheter Aortic Valve Replacement. Confirmation of Attendans ...Ass.Prof Flavio Ribichini. Rome, 27-28 June 2016 Organiser : European Association for Cardio Thoracic Surgery.

292. Dr. Flavio Ribichini participo en caracter de DISERTANTE EXTRANJERO en el tema: 5 del TOP 5 HEMODINAMIA Y TERAPEUTICA INVASIVA en el II Encuentro Internacional del Curso “”El continuo cardiovascular”” Hospital Universitario Austral y la Facultad de Ciencias Biomedicas de la Universidad Austral. Pilar, Prov. De Buenos Aires, 16 y 17 septiembre 2016.

293. F.Ribichini . Prof. Dott. Flavio Luciano Ribichini. Relatore, all”evento XLVII Congresso SIAPAV Sezione Triveneto. Verona 24 settembre 2016. La denervazione Renale in Veneto oggi.

294. Russian Society of Interventional Cardioangiology... 4rd. Annual International Course Modern Trends in the Treatment of SISTEMI from Guidelines to Daily Practice. LECTURE..Intravascular study in patients with acute coronary syndrome. October 5 – 7 2016.

295. XII European Bifurcation Club.-Rotterdam 14-15 october 2016.-Faculty

296. Attestato di Partecipazione di Flavio Luciano Ribichini, “Commentatore- Relatore” nel 37 Contresso Nazionale Societa Italiana di Cardiologia Interventistica. Genova 11- 14 ottobre 2016.

297. Simposio BIOTRONIC. Prof. Flavio Ribichini ---Relatore. Porto Antico, GENOVA. 12 Ottobre 2016.

298. PROF. DOTT. FLAVIO RIBICHINI, ha partecipato al Convegno Cardiologia NO LOGO Unanswered Questions, in qualita di relatore. Savoia Excelsior Palace Trieste, 21—22 ottobre 2016.

299. Hospital Cardiologico Costantini, certifica participacion en CARDIOINTERV. 2016 Dr. Flavio Ribichini, los días 24 y 25 de noviembre en Curitiba, en calidad de INVITADO EXTRANJERO, CHAIRMAN y ejecutor de casos live.

300. SORIN International Advisory Board Meeting, Invited Speaker on CT imaging for TAVI planning. Frankfurt December 15th 2016.

2017

301. Barcelona, Eurota Group

302. Amsterdam, Volcano-Philips Advisory Board

303. European Tech Exchange, Prague

304. Dusseldorf March 22. PCR Rtablator Seminar

305. Latin American Tech Exchange Panama City, April

306. CITIC April 27-28 Mexico City

307. PCR May 16-19, Paris

308. SAC Rosario 1-2 June

309. TCT Russia 8-10 June St.Petersburg

310. Imperial College, London 12-13 June

311. SBHCI, Natal , Brazil 21-23 June

312. SOLACI Buenos Aires, August 2-4

313. Rotablator European Advisory Board, Paris, September 14th

314. Verona, September 22 Arosio

315. London Valves London 24-26 September

316. Tyrolean Meeting of Cardiology. Bozen 29-30 September.

317. MDT Abdisory Meeting, Amsterdam 56- October

318. Verona, Astra Zeneca meeting 7 October

319. EMICS Milan 11-12 Octobe

- 320. GISE Milan, October 10-13
- 321. Verona per Girolomoni 27 Ottobre
- 322. Giornate Cardiologiche Torinesi 28 Ottobre.
- 323. Bolzano 4 Novembre
- 324. Cagliari 17-17 Novembre
- 325. SIC Roma 15-18 Dicembre

15. Elenco delle pubblicazioni di articoli “full text”.

1. Madoery C, Ribichini F, Galli B, Madoery R. Endocarditis infecciosa: Experiencia en el Hospital Privado, revisión de la literatura. *Experiencia Médica* 1988; 6: 3-19 **(F)**
2. Gastaldi L, Morello M, Casalucci D, Ribichini F, et al. European consensus on standards and guidelines for global and regional ventricular function from echocardiography: Parameters to assess myocardial contractility. *Echocardiography*, Chapter in book, Elsevier Publisher, 1990: 315-320 **(F)**
3. Gastaldi L, Morello M, Casalucci D, Ribichini F, et al. Overview and choice of parameters to assess myocardial contractility. 7th International Congress on Echocardiography. Rome 1990, 113-114. **(F)**
4. Madoery C, Farhy R, Ribichini F, et al. Tratamiento alternativo de la fibrilación auricular paroxística. *Revista Latina de Cardiología* 1991; 12: 264-67 **(R)**
5. Feola M, Ribichini F, Macchia G et al. Cardiopatía isquémica silenciosa en el diabete mellito: rol de la neuropatía diabética. *Rassegna Geriátrica* 1991; 27: 113-118 **(R)**
6. Steffenino G, Bobbio M, Orzan F, Ribichini F et al. Recidiva después de segunda angioplastia coronaria: ¿cuál es la elección terapéutica?. in *Librex Editori, Cardiología* 1991; Chapter in book Milano, p 337-342 **(F)**
7. Dellavalle A, Steffenino G, Ribichini F et al. Ambulatory cardiac catheterization. *G Ital Cardiol* 1993; 23: 973-977 **(R)**
8. Dellavalle A, Steffenino G, Ribichini F et al. Diagnóstico cardíaco invasivo en régimen ambulatorio protegido. *Cardiología* 1993;39:199-202 **(R)**
9. Feola M, Ribichini F, Gallone G et al. Right-sided chest ECG leads in 195 normal subjects. *G Ital Cardiol* 1994; 24: 375-379 **(R)**
10. Dellavalle A, Ribichini F, Steffenino G. Unrecognized infrahepatic interruption of inferior vena cava associated with floppy mitral valve prolapse, and severe mitral regurgitation. *Chest* 1994; 106: 1226-1228 **(F)**
11. Steffenino G, Dellavalle A, Ribichini F et al. Quality assurance and cost containment in invasive and interventional cardiology. *G Ital Cardiol* 1994; 24: 1055-1067 **(R)**
12. Russo P, Steffenino G, Dellavalle A, Ribichini F, Uslenghi E. Criterios clínicos e angiográficos para la selección de los pacientes para la PTCA con e sin stand-by cardiocirúrgico. In *New Trends in PTCA*. Chapter in book. Torino 1994; 21-28 **(F)**

13. Dellavalle A, Steffenino G, Ribichini F et al. Elective coronary angioplasty with and without surgical standby: clinical and angiographic criteria for the selection of patients. *Coronary Artery Disease* 1995; 6: 513-520 **(R)**
14. Dellavalle A, Steffenino G, Ribichini F, et al. Use of activated clotting time (ACT) for optimal heparin dosage during coronary angioplasty. *G Ital Cardiol* 1995; 25: 445-451 **(R)**
15. Russo P, Steffenino G, Dellavalle A, Ribichini F. Concomitant myocardial infarction in identical twins with similar coronary lesions. *G Ital Cardiol* 1995; 25: 341-343 **(R)**
16. Steffenino G, Ribichini F, Dellavalle A, Rossetti V, Cerati R, Garbarino M, Russo P, Uslenghi E. Radiological practice and radiation protection in italian cardiac catheterization laboratories. *Cardiologia* 1996; 41: 45-49 **(R)**
17. Steffenino G, Dellavalle A, Ribichini F et al. Ambulation after 3 hours after elective cardiac catheterisation through the femoral artery. *Br Heart J* 1996; 75: 477-480 **(F)**
18. Steffenino G, Dellavalle A, Ribichini F, Uslenghi E. Coronary stenting after unsuccessful emergency coronary angioplasty in acute myocardial infarction: Results in a series of consecutive patients. *Am Heart J* 1996; 132:1115-1118 **(R)**
19. Steffenino G, Rossetti V, Ribichini F, Dellavalle A, Garbarino M, Cerati R, Norbiato A, Uslenghi E. Staff dose reduction during coronary angiography using low framing speed. *Br J Radiol* 1996; 69: 860-864 **(F)**
20. Bruna C, Rossetti G, Vado A, Steffenino G, Dellavalle A, Ribichini F, Racca E, Ferrero V, Uslenghi E. Prediction of arrhythmic events in the first year after myocardial infarction treated with reperfusion therapy. VI Asia-Pacific symposium on cardiac pacing and electrophysiology. New Deli 25-28 October 1997 **(R)**
21. Bruna C, Vado A, Rossetti G, Racca E, Steffenino G, Dellavalle A, Ribichini F, Ferrero V, Uslenghi E. Effects of percutaneous transluminal coronary angioplasty in patients with evolving myocardial infarction on the signal-averaged electrocardiogram. *G Ital Cardiol* 1997; 27: 1144-1152 **(R)**
22. Weaver D, Simes J, Betriu A, Grines C, Zijlstra F, Garcia E, Grinfeld L, Gibbons R, Ribeiro E, DeWood M, Ribichini F. Primary coronary angioplasty vs. intravenous thrombolysis for treatment of acute myocardial infarction: A quantitative overview of their comparative effectiveness. *JAMA* 1997; 278: 2093-2098 **(F)**
23. Ribichini F, Steffenino G, Dellavalle A, et al. On-line quantitative coronary analysis in clinical practice: one step closer to reality? *Cathet Cardiovasc Diagn* 1994; 31: 102-109 **(R)**
24. Ribichini F, Steffenino G, Dellavalle A et al. Elective coronary angioplasty with no surgical back-up at all. *G Ital Cardiol* 1994; 24: 949-956 **(R)**

25. Ribichini F, Steffenino G, Dellavalle A et al. Emergency coronary angioplasty in high-risk acute myocardial infarction. *G Ital Cardiol* 1995; 25: 707-714 **(R)**
26. Ribichini F, Steffenino G, Dellavalle A, Uslenghi E. La angioplastia primaria como tratamiento de eleccìon en el infarto de miocardio de alto riesgo. Capitulo del libro: *Avances en Medicina '95*. Sociedad Argentina de Medicina, Buenos Aires 1995; 289-297 **(F)**
27. Ribichini F, Conte R, Lioi A Dellavalle A, Ugliengo G. Subacute tricuspid regurgitation with severe hypoxemia complicating blunt chest trauma. *Chest* 1996; 106: 289-291 **(R)**
28. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma Activity and Insertion/Deletion Polymorphism of Angiotensin-Converting Enzyme: A Major Risk Factor and a Marker of Risk for Coronary Stent Restenosis. *Circulation* 1998; 97:147-154 **(R)**
29. Ribichini F, Steffenino G, Dellavalle A, et al. Primary angioplasty in acute inferior myocardial infarction with anterior ST-segment depression: follow-up results. *G Ital Cardiol* 1998; 28:781-787 **(R)**
30. Ribichini F, Steffenino G, Dellavalle A, Rizzotti M. Use of Gianturco-Roubin stents for treating abrupt occlusion of unprotected left main stem during elective PTCA. *G Ital Cardiol* 1998; 28: 694-698 **(R)**
31. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma Lipoprotein (a) is not a predictor for restenosis after elective high-pressure coronary stenting. *Circulation* 1998; 98: 1172-1177 **(R)**
32. Ribichini F, Steffenino G, Dellavalle A, Ferrero V, Vado A, Feola M, Uslenghi E. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized trial. *J Am Coll Cardiol* 1998; 32:1687-1694 **(R)**
33. Ribichini F, Steffenino G, Dellavalle A, Russo P, Uslenghi E. L'impiego dello stent può estendere l'indicazione ad angioplastica coronarica nell'infarto acuto dopo trombolisi? *Controversie in Cardiologia*. 32° Convegno Internazionale di Cardiologia 1998, Milano 1998. Chapter in book, p 3-12 **(F)**
34. Ribichini F. L'enzima di conversione dell'angiotensina I e restenosi dopo angioplastica coronarica. *Emodinamica* 1999;15:16-21 **(R)**
35. Ribichini F, Uslenghi E. Polimorfismi dell'ACE e malattia coronarica. In *Ipertensione arteriosa e genetica*. Editato dalla Societa Italiana dell'Ipertensione Arteriosa. Torino 1999, chapter in book, p 47-54 **(F)**
36. Ribichini F. Controversies in coronary stenting: Conditional stenting is the way to go. Editorial. *G Ital Cardiol* 1999;29:495-504 **(R)**
37. Ribichini F, Wijns W. Genetic predictors of in-stent restenosis. *Remedica* 1999; 2:8-15 **(F)**

38. Ribichini F. Experiences with primary angioplasty without on-site cardiac surgery. *Sem Intervent Cardiol* 1999;4:47-53 **(R)**
39. Bruna C, Rossetti G, Vado A, Racca E, Steffenino G, Dellavalle A, Ribichini F, Ferrero V, Meinardi E, Uslenghi E. Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty. *G Ital Cardiol* 1998; 28:3-11 **(R)**
40. Ferrero V, Steffenino G, Meinardi F, Conte E, Deorsola A, Vado A, Ribichini F, Dellavalle A, Meinardi E, Uslenghi E. Early aggressive treatment of unstable angina without on-site cardiac surgical facilities: a prospective study of acute and long-term outcome. *G Ital Cardiol* 1998; 28:112-119 **(R)**
41. Antonini-Canterin F, Faggiano P, Zanuttini D, Ribichini F. Is aortic valve resistance more clinically meaningful than valve area in aortic stenosis? Editorial. *Heart* 1999;1:9-10 **(R)**
42. Conte L, Dutto S, Giachello G, Lice G, Tomatis M, Russo P, Dellavalle A, Ribichini F, Steffennino G. Cateterismo cardiaco per via arteriosa femorale con 4 French e mobilitazione a 2 ore. *G Ital Cardiol* 1999;29:529-532 **(R)**
43. Ribichini F, Pugno F, Ferrero V, Bussolati G, Di Mario C, Colombo A. Angiotensin-converting enzyme tissue activity in the diffuse in-stent restenotic plaque. *Circulation* 2000;101:e33-e35 **(R)**
44. Ribichini F, Matullo G, Piazza A, Vado A, Uslenghi E. Relationship between plasma ACE activity and the proliferative healing process in coronary vessel injury after coronary stenting. *Atherosclerosis* 2000;152: 261-263 **(R)**
45. Faggiano P, Antonini-Canterin F, Ribichini F, D'Aloia A, Ferrero V, Cervesato E, Pavan D, Burelli C, Nicolosi G. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. *Am J Cardiol* 2000; 85:204-208 **(F)**
46. Russo P, Steffenino G, Dellavalle A, Ribichini F, Ferrero V, Vado A, Uslenghi E. Angiographic follow-up after coronary implantation of the Multilink stent: a prospective observation. *Ital Heart J* 2000;1:117-121 **(R)**
47. Stewart MW, Smith RS, Ribichini F, Fringuellino M. The role of auditory input in sudden infant death syndrome: A brief review and hypothesis. *Prenat Neonat Med* 2000;5:9-16 **(F)**
48. Wijns W, Ribichini F. Editorial: CRP. Does it stand for coronary restenosis prediction? *Eur Heart J* 2000; 21:1121-1123 **(R)**
49. Guidelines 2000 for Cardiopulmonary resuscitation and emergency cardiovascular care. International consensus on science. Contributor. Supplement to *Circulation* 2000; 102 (8) August 22, 2000 **(F)**
50. Depres C, Ribichini F, Wijns W. Pathophysiological insights from studies on retrieved tissue. *Sem Intervent Cardiol* 2000;5:175-184 **(R)**

51. Aufderheide TP, Bossaer LL, Field J, Herlitz J, Leizorovicz A, Littrell KA, Ornato JP, Peberdy MA, Ribichini F. Acute Coronary Syndromes. *Ann Emerg Med* 2001; 27:S163-S181 **(e-R)**
52. Pugno F, Ribichini F. Osservazioni istopatologiche del materiale restenotico intrastent. *Pathologica* 2001;93:348 **(F)**
53. Ribichini F, Pugno F. Lesioni coronariche e carotidee arteriosclerotiche. *Pathologica* 2001;93:349-350 **(F)**
54. Ribichini F. In Stent Restenosis. Current Perspective. *Ital Heart J* 2001;2:728-735 **(R)**
55. Ribichini F. Primary angioplasty to treat acute myocardial infarction. *International Cardiology*. Spring issue 2002 **(F)**
56. Ribichini F, Pugno F, Di Mario C. Microscopic evidence of effective ablation of calcium and metal from coronary arteries treated with directional coronary atherectomy using the Flexicut device. *Heart* 2002; 87:283 **(e-R)**
57. Ribichini F, Wijns W. Reperfusion treatment of acute myocardial infarction. Educational Article. *Heart* 2002; 88: 298-305 **(e-R)**
58. Ribichini F, Ferrero V, Wijns W, Matullo G, Piazza A, Uslenghi E. Can ACE Inhibitors promote detrimental vascular effects after percutaneous injury? *Hypertension* 2002; 40: e5-6 **(R)**
59. Ribichini F, Ferrero V, Vassanelli C. Logistics of primary angioplasty. Rather few centralized centers or better knowledge at local hospitals?. *Heart Drug* 2002; 2:321-325 **(R)**
60. Rougin A, Ribichini F, Ferrero V, Heller H, Wijns W, Levy A. Haptoglobin phenotype and the risk of restenosis after coronary artery stent implantation. *Am J Cardiol* 2002; 89: 806-810 **(e-R)**
61. Feola M, Biggi A, Ribichini F, Rovere E, Camuzzini GF, Uslenghi E. Usefulness of Tl 201dipyridamole myocardial scintigraphy to predict cardiac events in renal transplant recipients. *J of Nephrology* 2002; 5: 48-53 **(R)**
62. Takagi T, Di Mario C, Stankovic G, Reimers B, Alberti A, Liistro F, Kovalenko O, Sgura F, Albiero R, Ribichini F, Pugno F, Colombo A. Effective plaque removal with a new 8 French-compatible atherectomy catheter. *Catheter Cardiovasc Interv*. 2002; 56: 452-9 **(e-R)**
63. Feola M, Biggi A, Ribichini F, Camuzzini G, Uslenghi E. The diagnosis of coronary artery disease in hypertensive patients with chest pain and complete left bundle branch block: utility of adenosine Tc99m tetrofosmin SPECT. *Clin Nucl Med* 2002; 27: 510-515 **(R)**
64. Zijlstra F, Patel A, Jones M, Grines C, Ellis S, Garcia E, Grinfeld L, Gibbons RJ, Ribeiro EE, Ribichini F, Granger C, Akhras F, Weaver D, Simes J for the PCAT collaboration. Clinical characteristics and outcome of patients with early (<2 hours), intermediate (2-4 hours) and late (>4 hours) presentation treated with primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. *Eur Heart J* 2002; 23:550-557 **(e-R)**

65. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, Ghini AS, et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS-Study). *J Am Coll Cardiol* 2002; 40:1935-42 **(e-R)**
66. Ribichini F, Wijns W, Ferrero V, Matullo G, Camilla T, Guarrera S, Vado A, Piazza A, Uslenghi E. Effect of angiotensin-converting enzyme inhibition and restenosis after coronary stenting. *Am J Cardiol* 2003;91:154-158 (R)
67. PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: Six-month follow-up and analysis of individual patient data from randomized trials. *Am Heart J* 2003; 145: 47-57 **(e-R)**
68. The Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. *Circulation* 2003;107:1117-1122 **(e-R)**
69. Feola M, Menardi E, Ribichini F, Vado A, Visconti G, Milanese U, Uslenghi E. Effect of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure. *Med Sci Monit* 2003;8:341-345 **(R)**
70. Ferrero V, Ribichini F, Boccuzzi G, Vassanelli C. I sistemi di protezioni distale nell'angioplastica coronarica. *Emodinamica* 2003;32:21-29. **(e-R)**
71. Ferrero V, Ribichini F, Matullo G, Guarrera S, Carturan S, Vado A, Vassanelli C, Piazza A, Uslenghi E, Wijns W. Estrogen receptor- α polymorphisms and angiographic outcome after coronary artery stenting. *Arterioscler Thromb Vasc Biol* 2003;23:2223-2228 **(R)**

2004

72. Ribichini F, Ferrero V, Matullo, et al. Association study of the I/D polymorphism and plasma ACE as risk factors for stent restenosis. *Clin Sci* 2004; 107: 381-389 (R)
73. Ribichini F, Ferrero V, Boccuzzi G, Carriero A, Vassanelli C. Marcatori genetici della restenosi post-angioplastica. *Emodinamica* 2004;2:11-21 (R)
74. Ribichini F, Ferrero V, Wijns W. Reperfusion treatment of ST elevation acute myocardial infarction. Review. *Prog Cardiovasc Disease* 2004; 47: 131-157 (R)
75. Feola M, Biggi A, Vado A, Ribichini F, Ferrero V, Leonardi G, Uslenghi E. Usefulness of adenosine Tc-99m tetrofosmin SPECT for the diagnosis of left anterior descending coronary artery disease in patients with chest pain and left bundle branch block. *Nucl Med Commun* 2004; 25:265-269 **(R)**
76. Feola M, Biggi A, Francini A, Leonardi G, Ribichini F, Ferrero V, Uslenghi E. Trimetazidine improves myocardial perfusion and left ventricular function in ischemic left ventricular dysfunction. *Clin Nucl Med* 2004; 29: 117-118 **(F)**

77. Bertona R, De Candia GF, Boccuzzi G, Ribichini F, Agostini M, Vassanelli C. Stenosi del corpo del graft di arteria mammaria interna sinistra. Aterosclerosi, spasmo o kinking? *Ital Heart J* 2004; 5: 53-58 **(R)**
78. Feola M, Ribichini F, Ferrero V, et al. Comparison of Frequency of Insulin Resistance After Coronary Stenting in Patients with Type 2 Diabetes Mellitus With-vs-Without Coronary Restenosis. *Am J Cardiol* 2004; 94: 777-780 **(R)**
79. Agostini M, Ribichini F, Portolan M, et al. Giant fistula connecting left coronary sinus with superior atriocaval junction. *Ital Heart J* 2004; 6: 483-5 **(R)**.
80. Feola M, Biggi A, Francini A, Leonardi G, Ribichini F, Ferrero V, Uslenghi E. The acute administration of trimetazidine modified myocardial perfusion and left ventricular function in 31 patients with ischemic ventricular dysfunction. *Int J Cardiovasc Imaging* 2004; 20: 315-320 **(F)**
81. Ferrero V, Ribichini F, Heyndrickx G, De Bruyne B, Piessens M, Carlier S, et al. Angiographic and three-dimensional intravascular ultrasound analysis of combined intracoronary beta radiation and self-expanding stent implantation in human coronary arteries. *Am J Cardiol* 2004; 94: 1237-1242 **(e-R)**

2005

82. Ribichini F, Maffe S, Ferrero V, Cotroneo A, Vassanelli C. Percutaneous angioplasty of the subclavian artery angioplasty in patients with mammary-coronary by pass grafts. *J Interven Cardiol* 2005; 18: 39-44 **(e-R)**
83. Ribichini F, Ferrero V, Rognoni A, Vacca G, Vassanelli C. Angiotensin Antagonism in Coronary Artery Disease: Results After Coronary Revascularization. *Drugs* 2005;65:1073-1096 **(R)**
84. Ribichini F, Tomai F, Ferrero V, Versaci F, Boccuzzi G, Proietti I, Prati F, Crea F, Vassanelli C. Immunosuppressive oral prednisone after percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS-2/MVD study. *Eurointervention* 2005;2:173-180 **(e-R)**
85. Ribichini F, Ferrero V, Heyndrickx GR, et al. Intracoronary Beta-Irradiation Prevents Excessive In-Stent Neointimal Proliferation in De-Novo Lesions of Patients With High Plasma ACE Levels. The *BetAce* Randomized Trial. *Cardiovasc Revasc Med* 2005;6:7-13 **(R)**
86. Ribichini F, Ferrero V, Agostini M, Vassanelli C. Immunosuppression against restenosis. Efficacy of a radiofrequency guidewire and oral prednisone in achieving and maintaining coronary artery patency after stenting. *Cardiovasc Revasc Med* 2005;6:124-125 **(e-R)**
87. Mannucci PM, Bernardinelli L, Foco L, Galli M, Ribichini F, Tubaro M, Peyvandi F. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. *J Thromb Haemost* 2005; 3: 280-286 **(e-R)**

88. Tomai F, Ribichini F, Ghini AS, Ferrero V, et al. Elevated C-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease. *Eur Heart J* 2005;26:2099-2105 (e-R)
89. Airoidi F, Di Mario C, Ribichini F, Presbitero P, Sganzerla P, Ferrero V, Vassanelli C, Briguori C, Carlino M, Montorfano, et al. 17-beta estradiol eluting stent versus PC-coated stent for the treatment of native coronary artery disease: clinical and angiographic results of the Italian EASTER trial. *Am J Cardiol* 2005;96:664

2006

90. Ribichini F, Pugno F, Ferrero V, Bussolati G, Feola M, Russo P, Di Mario C, Colombo A, Vassanelli C. Cellular immunostaining of angiotensin-converting enzyme in human coronary atherosclerotic plaques. *J Am Coll Cardiol* 2006;47:1143-9 (e-R)
91. Feola M, Bigi A, Francini A, Leonardi G, Vado A, Ribichini F, Uslenghi E. Placebo or trimetazidine 99mTC tetrofosmin myocardial SPECT and low-dose dobutamine echocardiography in hibernating myocardium. *Arch Med Res* 2006;37:117-122 (e-R)
92. Grossini F, Molinari C, Battaglia A, Mary D.A.S.G, Ribichini F, Surico N, Vacca G. Human placental lactogen decreases regional blood flow in anesthetized pigs. *J Vasc Res* 2006;43:205-213 (e-R)
93. Molinari C, Grossini F, Mary DA, Ribichini F, Surico N, Vacca G. The role of nitric oxide in the peripheral vasoconstriction caused by human placental lactogen in anaesthetized pigs. *Exp Physiol.* 2006 May;91(3):603-10. Epub 2006 Mar 2.
94. Reversible inverse mismatch in transient left ventricular apical ballooning: perfusion/metabolism positron emission tomography imaging. Feola M, Rosso GL, Casasso F, Morena L, Biggi A, Chauvie S, **Ribichini F**, Uslenghi E. *J Nucl Cardiol.* 2006 Jul;13(4):587-90.

2007

96. Glucocorticoids in the prevention of restenosis after coronary angioplasty: therapeutic potential. Ferrero V, **Ribichini F**, Pesarini G, Brunelleschi S, Vassanelli C. *Drugs.* 2007;67(9):1243-55. Review.
97. Successful surgical treatment of a giant coronary aneurysm communicating with the right atrium. Rognoni A, Ferrero V, Teodori G, **Ribichini F**. *J Cardiovasc Med (Hagerstown).* 2007 Dec;8(12):1061-4.

98. Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions.

Ribichini F, Ferrero V, Feola M, Rognoni A, Brunelleschi S, Vacca G, Vassanelli C.

J Interv Cardiol. 2007 Jun;20(3):209-13.

99. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms.

Molinari C, Grossini E, Mary DA, Uberti F, Ghigo E, **Ribichini F**, Surico N, Vacca G.

Endocrinology. 2007 Aug;148(8):4080-90. Epub 2007 Apr 26.

100. Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study).

Ferrero V, **Ribichini F**, Rognoni A, Marino P, Brunelleschi S, Vassanelli C.

Am J Cardiol. 2007 Apr 15;99(8):1082-6. Epub 2007 Mar 6.

101. Percutaneous treatment of coronary bifurcations: lesion preparation before provisional bare metal stenting and subsequent immunosuppression with oral prednisone. The IMPRESS-Y study.

Ribichini F, Ferrero V, Rognoni A, Marino P, Brunelleschi S, Vassanelli C.

J Interv Cardiol. 2007 Apr;20(2):114-21.

102. Intracoronary beta-irradiation for the treatment of de novo lesions: 5-year clinical follow-up of the BetAce randomized trial.

Ferrero V, **Ribichini F**, Piessens M, Heyndrickx GR, Verbeke L, de Bruyne B, Feola M, Vassanelli C, Wijns W.

Am Heart J. 2007 Mar;153(3):398-402.

103. Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry.

Ribichini F, Tomai F, Paloscia L, Di Sciascio G, Carosio G, Romano M, Verna E, Galli M, Tamburino C, De Cesare N, Pirisi R, Piscione F, Lanteri G, Ferrero V, Vassanelli C; DESIRE investigators.

Heart. 2007 May;93(5):598-600. Epub 2006 Sep 27.

104. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis.

Ribichini F, Joner M, Ferrero V, Finn AV, Crimins J, Nakazawa G, Acampado E, Kolodgie FD, Vassanelli C, Virmani R.

J Am Coll Cardiol. 2007 Jul 10;50(2):176-85. Epub 2007 Jun 22.

2008

105. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.

Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Giofrè G, Prati F, Tamburino C, **Ribichini F**.

Diabetes Care. 2008 Jan;31(1):15-9. Epub 2007 Oct 1.

106. Long-term histological and immunohistochemical findings in human venous aorto-coronary bypass grafts.

Ribichini F, Pugno F, Ferrero V, Wijns W, Vacca G, Vassanelli C, Virmani R.

Clin Sci (Lond). 2008 Feb;114(3):211-20.

107. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus-versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial.

Chevalier B, Di Mario C, Neumann FJ, **Ribichini F**, Urban P, Popma JJ, Fitzgerald PJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Schwartz LB; ZoMaxx I Investigators.

JACC Cardiovasc Interv. 2008 Oct;1(5):524-32. doi: 10.1016/j.jcin.2008.08.010.

108. Drug-eluting stent safety: findings from preclinical studies.

Nakazawa G, Finn AV, Ladich E, **Ribichini F**, Coleman L, Kolodgie FD, Virmani R.

Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1379-91. doi: 10.1586/14779072.6.10.1379. Review.

109. Reversible impairment of coronary flow reserve in takotsubo cardiomyopathy: a myocardial PET study.

Feola M, Chauvie S, Rosso GL, Biggi A, **Ribichini F**, Bobbio M.

J Nucl Cardiol. 2008 Nov-Dec;15(6):811-7. doi: 10.1007/BF03007363. Epub 2008 Jul 31.

110. Percutaneous Impella Recover circulatory support in high-risk coronary angioplasty.

Arieti M, Pesarini G, **Ribichini F**.

Cardiovasc Revasc Med. 2008 Oct-Dec;9(4):269-74. doi: 10.1016/j.carrev.2008.04.004.

111. Cystatin C and contrast-induced nephropathy.

Gambaro G, Graziani MS, **Ribichini F**.

Nephrol Dial Transplant. 2008 Dec;23(12):4079; author reply 4079-80. doi: 10.1093/ndt/gfn507. Epub 2008 Sep 6. No abstract available.

112. Myocardial scar and insulin resistance predict cardiovascular events in severe ischaemic myocardial dysfunction: a perfusion-metabolism positron emission tomography study.

Feola M, Biggi A, Chauvie S, Vado A, Leonardi G, Rolfo F, **Ribichini F**.

Nucl Med Commun. 2008 May;29(5):448-54. doi: 10.1097/MNM.0b013e3282f5d2bc.

113. A novel activity for substance P: stimulation of peroxisome proliferator-activated receptor-gamma protein expression in human monocytes and macrophages.

Amoruso A, Bardelli C, Gunella G, **Ribichini F**, Brunelleschi S.

Br J Pharmacol. 2008 May;154(1):144-52. doi: 10.1038/bjp.2008.50. Epub 2008 Feb 18.

2009

114. Long-term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C-reactive protein levels.

Ferrero V, Tomai F, Versaci F, Feola M, Proietti I, Rognoni A, Ghini AS, Gaspardone A, Vacca G, De Luca L, Vassanelli C, **Ribichini F**.

EuroIntervention. 2009 Jun;5(2):250-4.

115. Primary percutaneous coronary intervention: different outcome for different subgroups?

Savonitto S, Briguori C, **Ribichini F**, Tomai F, Piccaluga E.

J Cardiovasc Med (Hagerstown). 2009 Oct;10 Suppl 1:S27-34. doi:

116. Tobacco smoke affects expression of peroxisome proliferator-activated receptor-gamma in monocyte/macrophages of patients with coronary heart disease.

Amoruso A, Gunella G, Rondano E, Bardelli C, Fresu LG, Ferrero V, **Ribichini F**, Vassanelli C, Brunelleschi S.

Br J Pharmacol. 2009 Nov;158(5):1276-84. doi: 10.1111/j.1476-5381.2009.00442.x. Epub 2009

117. Enhanced peroxisome proliferator-activated receptor-gamma expression in monocyte/macrophages from coronary artery disease patients and possible gender differences.

Amoruso A, Bardelli C, Fresu LG, Palma A, Vidali M, Ferrero V, **Ribichini F**, Vassanelli C, Brunelleschi S.

J Pharmacol Exp Ther. 2009 Nov;331(2):531-8. doi: 10.1124/jpet.109.154419. Epub 2009 Jul 30.

118. On the current epidemic outburst of meta-analytic rage in interventional cardiology.

Agostoni P, **Ribichini F**, Wijns W.

EuroIntervention. 2009 May;5(1):19-23. No abstract available.

119. Percutaneous transcatheter balloon valvuloplasty for severe tricuspid valve stenosis in Ebstein's anomaly.

Boccuzzi G, Gigli N, Cian D, Vullo C, Bonomini L, **Ribichini F**, Portella G, Strada G.

J Cardiovasc Med (Hagerstown). 2009 Jun;10(6):510-5.

120. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.

Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F, De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C.

J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):192-9. doi: 10.2459/JCM.0b013e32831f9176.

121. Recurrent very late drug-eluting stent thrombosis.

Pesarini G, Arieti M, Spadaro R, Vassanelli C, **Ribichini F**.

Cardiovasc Revasc Med. 2009 Apr-Jun;10(2):130-5. doi: 10.1016/j.carrev.2008.06.005.

122. Steroid-eluting stents in patients with acute coronary syndromes. Angiographic results of DESIRE: Dexamethasone-Eluting Stent Italian REgistry.

Pesarini G, Ferrero V, Tomai F, Paloscia L, De Cesare N, Tamburino C, Piscione F, Vassanelli F, **Ribichini F**; Dexamethasone-Eluting Stent Italian REgistry Investigators.

J Invasive Cardiol. 2009 Mar;21(3):86-91.

123. Urocortin II induces nitric oxide production through cAMP and Ca²⁺ related pathways in endothelial cells.

Grossini E, Molinari C, Mary DA, Uberti F, **Ribichini F**, Caimmi PP, Vacca G.

Cell Physiol Biochem. 2009;23(1-3):87-96. doi: 10.1159/000204097. Epub 2009 Feb 18.

124. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants.

Myocardial Infarction Genetics Consortium, Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H, Erdmann J, Reilly MP, Rader DJ, Morgan T, Spertus JA, Stoll M, Girelli D, McKeown PP, Patterson CC, Siscovick DS, O'Donnell CJ, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Melander O, Altshuler D, Ardissino D, Merlini PA, Berzuini C, Bernardinelli L, Peyvandi F, Tubaro M, Celli P, Ferrario M, Fétiqueau R, Marziliano N, Casari G, Galli M, **Ribichini F**, Rossi M, Bernardi F, Zoncin P, Piazza A, Mannucci PM, Schwartz SM, Siscovick DS, Yee J, Friedlander Y, Elosua R, Marrugat J, Lucas G, Subirana I, Sala J, Ramos R, Kathiresan S, Meigs JB, Williams G, Nathan DM, MacRae CA, O'Donnell CJ, Salomaa V, Havulinna AS, Peltonen L, Melander O, Berglund G, Voight BF, Kathiresan S, Hirschhorn JN, Asselta R, Duga S, Sreafico M, Musunuru K, Daly MJ, Purcell S, Voight BF, Purcell S, Nemesh J, Korn JM, McCarroll SA, Schwartz SM, Yee J, Kathiresan S, Lucas G, Subirana I, Elosua R, Surti A, Guiducci C, Gianniny L, Mirel D, Parkin M, Burt N, Gabriel SB, Samani NJ, Thompson JR, Braund PS, Wright BJ, Balmforth AJ, Ball SG, Hall A; Wellcome Trust Case Control Consortium, Schunkert H, Erdmann J, Linsel-Nitschke P, Lieb W, Ziegler A, König I, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Schunkert H, Samani NJ, Erdmann J, Ouwehand W, Hengstenberg C, Deloukas P, Scholz M, Cambien F, Reilly MP, Li M, Chen Z, Wilensky R, Matthai W, Qasim A, Hakonarson HH, Devaney J, Burnett MS, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Knouff CW, Waterworth DM, Walker MC, Mooser V, Epstein SE, Rader DJ, Scheffold T, Berger K, Stoll M, Häge A, Girelli D, Martinelli N, Olivieri O, Corrocher R, Morgan T, Spertus JA, McKeown P, Patterson CC, Schunkert H, Erdmann E, Linsel-Nitschke P, Lieb W, Ziegler A, König IR, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Hólm H, Thorleifsson G, Thorsteinsdóttir U, Stefansson K, Engert JC, Do R, Xie C, Anand S, Kathiresan S, Ardissino D, Mannucci PM,

Siscovick D, O'Donnell CJ, Samani NJ, Melander O, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Altshuler D.

Nat Genet. 2009 Mar;41(3):334-41. doi: 10.1038/ng.327. Epub 2009 Feb 8. Erratum in: Nat Genet. 2009 Jun;41(6):762. Knouff, Christopher W [added]; Waterworth, Dawn M [added]; Walker, Max C [added]; Mooser, Vincent [added].

125. Quinaprilat-eluting stents do not attenuate intimal thickening following stenting in porcine coronary arteries.

van Beusekom HM, Ferrero V, **Ribichini F**, van der Giessen WJ.

Atherosclerosis. 2009 Jul;205(1):120-5. doi: 10.1016/j.atherosclerosis.2008.11.029. Epub 2008 Dec

2010

126. Clinical outcome after endovascular, surgical or hybrid revascularisation in patients with combined carotid and coronary artery disease: the Finalised Research In ENDOvascular Strategies Study Group (FRIENDS).

Ribichini F, Tomai F, Reimers B, Russo P, Borioni R, Spartà D, Pacchioni A, Pesarini G, Spagnolo B, De Persio G, Cremonesi A, Castriota F.

EuroIntervention. 2010 Aug;6(3):328-35. doi: 10.4244/EIJV6I3A55.

127. Guidelines on myocardial revascularization.

Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Kolh P, Wijns W, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirllet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D.

Eur J Cardiothorac Surg. 2010 Sep;38 Suppl:S1-S52. doi: 10.1016/j.ejcts.2010.08.019. No abstract available.

128. Guidelines on myocardial revascularization.

Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirllet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D.

Eur Heart J. 2010 Oct;31(20):2501-55. doi: 10.1093/eurheartj/ehq277. Epub 2010 Aug 29. No abstract available.

129. Early creatinine shifts predict contrast-induced nephropathy and persistent renal damage after angiography.

Ribichini F, Graziani M, Gambaro G, Pasoli P, Pighi M, Pesarini G, Abaterusso C, Yabarek T, Brunelleschi S, Rizzotti P, Lupo A, Vassanelli C.

Am J Med. 2010 Aug;123(8):755-63. doi: 10.1016/j.amjmed.2010.02.026.

130. The gap between vascular interventions and vascular medicine.

Ribichini F, Tomai F, Castriota F, Russo P, Reimers B.

EuroIntervention. 2010 May;6(1):25-7. doi: 10.4244/. No abstract available.

131. Cytokines release inhibition from activated monocytes, and reduction of in-stent neointimal growth in humans.

Pesarini G, Amoroso A, Ferrero V, Bardelli C, Fresu LG, Perobelli L, Scappini P, De Luca G, Brunelleschi S, Vassanelli C, **Ribichini F**.

Atherosclerosis. 2010 Jul;211(1):242-8. doi: 10.1016/j.atherosclerosis.2010.02.004. Epub 2010 Feb

132. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease. Study design and rationale of the EXECUTIVE trial.

Ribichini F, Ansalone G, Bartorelli A, Beqaraj F, Berni A, Colangelo S, D'Amico M, Della Rovere F, Fiscella A, Gabrielli G, Indolfi C, La Vecchia L, Loschiavo P, Marinoni G, Marzocchi A, Milazzo D, Romano M, Sangiorgio P, Sheiban I, Tamburino C, Tuccillo B, Villani R, Cappi B, Quijada MJ, Vassanelli C; EXECUTIVE Trial Investigators.

J Cardiovasc Med (Hagerstown). 2010 Apr;11(4):299-309. doi: 10.2459/JCM.0b013e3283331e69.

133. Rationale and design of the Randomized comparison of XiEnce V and Multilink Vision coronary stents in the sAme muLtivessel patient with chronic kiDnEy disease (RENAL-DES) study.

Tomai F, Petrolini A, De Luca L, Nudi F, Lanza G, Vassanelli C, **Ribichini F**.

J Cardiovasc Med (Hagerstown). 2010 Apr;11(4):310-7. doi: 10.2459/JCM.0b013e3283347e24.

2011

134. Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarction.

Ardissino D, Berzuini C, Merlini PA, Mannuccio Mannucci P, Surti A, Burt N, Voight B, Tubaro M, Peyvandi F, Spreafico M, Celli P, Lina D, Notarangelo MF, Ferrario M, Fétiqueau R, Casari G, Galli M, **Ribichini F**, Rossi ML, Bernardi F, Marziliano N, Zonzin P, Mauri F, Piazza A, Foco L, Bernardinelli L, Altshuler D, Kathiresan S; Italian Atherosclerosis, Thrombosis and Vascular Biology Investigators.

J Am Coll Cardiol. 2011 Jul 19;58(4):426-34. doi: 10.1016/j.jacc.2010.11.075.

135. Early and long-term outcomes after combined percutaneous revascularization in patients with carotid and coronary artery stenoses.

Tomai F, Pesarini G, Castriota F, Reimers B, De Luca L, De Persio G, Spartà D, Aurigemma C, Pacchioni A, Spagnolo B, Cremonesi A, **Ribichini F**; Finalized Research in Endovascular Strategies Study Group.

JACC Cardiovasc Interv. 2011 May;4(5):560-8. doi: 10.1016/j.jcin.2011.01.012.

136. Implications of new ESC/EACTS guidelines on myocardial revascularization for patients with multivessel coronary artery disease.

Ribichini F, Taggart D.

Interact Cardiovasc Thorac Surg. 2011 May;12(5):663-6. doi: 10.1510/icvts.2010.261024. No abstract available.

137. Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI. A multicenter randomized trial.

Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Abukaresh R, Aurigemma C, De Luca L, Zavalloni D, Soregaroli D, Marino P, Garbo R, Zanolli L, Vassanelli C; CEREAS-DES investigators.

Am J Med. 2011 May;124(5):434-43. doi: 10.1016/j.amjmed.2010.11.027.

138. Venovenous extracorporeal membrane oxygenation as a bridge to and support for pulmonary thromboendarterectomy in misdiagnosed chronic thromboembolic pulmonary hypertension.

Faggian G, Onorati F, Chiominto B, Gottin L, Dan M, **Ribichini F**, Menon T, Santini F, Mazzucco A.

Artif Organs. 2011 Oct;35(10):956-60. doi: 10.1111/j.1525-1594.2010.01182.x. Epub 2011 Apr 14.

139. Implications of new ESC/EACTS guidelines on myocardial revascularisation for patients with multi-vessel coronary artery disease.

Ribichini F, Taggart D.

Eur J Cardiothorac Surg. 2011 May;39(5):619-22. doi: 10.1016/j.ejcts.2011.02.029. No abstract available.

140. Letter by Ribichini et al regarding article, "Cystatin C and contrast-induced acute kidney injury".

Ribichini F, Pesarini G, Gambaro G.

Circulation. 2011 Feb 8;123(5):e225; author reply e226.

doi: 10.1161/CIRCULATIONAHA.110.975672. No abstract available.

141. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.

Valgimigli M, Campo G, Malagutti P, Anselmi M, Bolognese L, **Ribichini F**, Boccuzzi G, de Cesare N, Rodriguez AE, Russo F, Moreno R, Biondi-Zoccai G, Penzo C, Díaz Fernández JF, Parrinello G, Ferrari R.

JACC Cardiovasc Interv. 2011 Jan;4(1):51-62. doi: 10.1016/j.jcin.2010.09.016.

142. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies.

Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium, Martinelli N, Girelli D, Quyyumi AA, Anderson JL, Erdmann J, Hall AS, Schunkert H, Quertermous T, Blankenberg S, Hazen SL, Roberts R, Kathiresan S, Samani NJ, Epstein SE, Rader DJ.

Lancet. 2011 Jan 29;377(9763):383-92. doi: 10.1016/S0140-6736(10)61996-4. Epub 2011 Jan 14.

2012

143. Hypothesis-based analysis of gene-gene interactions and risk of myocardial infarction.

Lucas G, Lluís-Ganella C, Subirana I, Musameh MD, Gonzalez JR, Nelson CP, Sentí M; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium, Schwartz SM, Siscovick D, O'Donnell CJ, Melander O, Salomaa V, Purcell S, Altshuler D, Samani NJ, Kathiresan S, Elosua R.

PLoS One. 2012;7(8):e41730. Epub 2012 Aug 2.

144. Is transfemoral aortic valve implantation possible without contrast medium in patients with renal and multiorgan failure?

Dandale R, Pesarini G, Santini F, Rossi A, Milano A, Faggian G, **Ribichini F**.

Future Cardiol. 2012 Jul;8(4):543-6. doi: 10.2217/fca.12.29.

145. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.

Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, Sangiorgi D, Bacchi Reggiani L, Kaiser C, Kim HS, De Waha A, **Ribichini F**, Stone GW.

Circ Cardiovasc Interv. 2012 Jun;5(3):357-64. doi: 10.1161/CIRCINTERVENTIONS.111.967083.

146. Transfemoral Edwards-Novaflex valve implantation in a patient with aorto-iliac endoprosthesis and severely tortuous bilateral external iliac arteries-"Railing track".

Dandale RM, Pesarini G, Santini F, Molinari G, Rossi A, Milano A, Faggian G, Vassanelli C, **Ribichini F**.

Cardiovasc Revasc Med. 2012 May-Jun;13(3):203.e5-8. doi: 10.1016/j.carrev.2012.02.004. Epub 2012 Apr 18.

147. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis.

Stahl EA, Wegmann D, Trynka G, Gutierrez-Achury J, Do R, Voight BF, Kraft P, Chen R, Kallberg HJ, Kurreeman FA; Diabetes Genetics Replication and Meta-analysis Consortium; Myocardial Infarction Genetics Consortium, Kathiresan S, Wijmenga C, Gregersen PK, Alfredsson L, Siminovitch KA, Worthington J, de Bakker PI, Raychaudhuri S, Plenge RM.

Nat Genet. 2012 Mar 25;44(5):483-9. doi: 10.1038/ng.2232.

148. [Diagnosis of acute renal injury by serum creatinine: negative perception vs evidence].

Gambaro G, Graziani MS, **Ribichini F**.

G Ital Nefrol. 2012 Jan-Feb;29(1):4-6. Italian. No abstract available.

149. Regarding 'Early postoperative serum cystatin C predicts severe acute kidney injury following pediatric cardiac surgery'.

Gambaro G, Graziana MS, **Ribichini F**.

Kidney Int. 2012 Mar;81(6):598; author reply 598-9. doi: 10.1038/ki.2011.429. No abstract available.

150. A model of multi-disciplinary approach to the diagnosis and treatment of young patients with cryptogenic stroke and patent foramen ovale.

Mazzucco S, Bovi P, Carletti M, Tomelleri G, Golia G, Stegagno C, Variola A, Anselmi M, Nicolis D, Olivato S, Anzola GP, **Ribichini F**; VEROSTROKE Study Group.

Cardiol Young. 2012 Jun;22(3):327-34. doi: 10.1017/S1047951112000029. Epub 2012 Feb 21.

151. Management of combined severe carotid and coronary artery disease.

Roffi M, **Ribichini F**, Castriota F, Cremonesi A.

Curr Cardiol Rep. 2012 Apr;14(2):125-34. doi: 10.1007/s11886-012-0246-1. Review.

152. First successful management of aortic valve insufficiency associated with HeartMate II left ventricular assist device support by transfemoral CoreValve implantation: the Columbus's egg?

Santini F, Forni A, Dandale R, **Ribichini F**, Rossi A, Franchi G, Onorati F, Vassanelli C, Mazzucco A, Faggian G.

JACC Cardiovasc Interv. 2012 Jan;5(1):114-5. doi: 10.1016/j.jcin.2011.10.009. No abstract available.

153. Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions.

Ribichini F, Gambaro G, Graziani MS, Pighi M, Pesarini G, Pasoli P, Anselmi M, Ferrero V, Yabarek T, Sorio A, Rizzotti P, Lupo A, Vassanelli C.

Clin Chem. 2012 Feb;58(2):458-64. doi: 10.1373/clinchem.2011.170464. Epub 2011 Dec 13.

154. Risk stratification in acute coronary syndromes.

Pesarini G, Santini F, Geremia G, Zivelonghi C, **Ribichini F**.

J Cardiovasc Transl Res. 2012 Feb;5(1):1-10. doi: 10.1007/s12265-011-9337-4. Epub 2011 Dec 2.

2013

155. Invasive assessment of renal artery atherosclerotic disease and resistant hypertension before renal sympathetic denervation.

Ribichini F, Pighi M, Zivelonghi C, Gambaro A, Valvo E, Lupo A, Vassanelli C.

J Nephrol. 2013 Jul-Aug;26(4):799-801. doi: 10.5301/jn.5000295. Epub 2013 Jun 28.

156. Numbers needed to treat (lives!) and numbers needed to save (money).

Ribichini F, Taggart D, Vassanelli C.

EuroIntervention. 2013 Jun 22;9(2):175-7. doi: 10.4244/EIJV9I2A28. No abstract available.

157. Late and very late coronary stent thrombosis: Intravascular ultrasound findings and associations with antiplatelet therapy.

Pesarini G, Dandale R, Rigamonti A, Pighi M, Zivelonghi C, Mugnolo A, Ferrero V, Vassanelli C, **Ribichini F**.

Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1056-65. doi: 10.1002/ccd.24938. Epub 2013 Jun 10.

158. Effects of prednisone on biomarkers of tubular damage induced by radiocontrast in interventional cardiology.

Ribichini F, Gambaro A, Pighi M, Pesarini G, Ferraro PM, Zuppi C, Baroni S, Penitente R, Ferrero V, Vassanelli C.

J Nephrol. 2013 May-Jun;26(3):586-93. doi: 10.5301/jn.5000266. Epub 2013 Mar 29.

159. Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES versus BMS alone to Eliminate Restenosis (CEREA-DES).

Ribichini F, Tomai F, Pesarini G, Zivelonghi C, Rognoni A, De Luca G, Boccuzzi G, Presbitero P, Ferrero V, Ghini AS, Marino P, Vassanelli C; CEREAS-DES Investigators.

Eur Heart J. 2013 Jun;34(23):1740-8. doi: 10.1093/eurheartj/eh079. Epub 2013 Mar 14.

160. Prevalence of patients with severely reduced aortic valve area and low gradient despite a preserved ejection fraction. Results from a cath-lab data base.

Benfari G, Rossi A, Dandale R, Toniolo M, Cristoforetti A, **Ribichini F**, Vassanelli C.

Int J Cardiol. 2013 Sep 10;167(6):3034-6. doi: 10.1016/j.ijcard.2012.11.098. Epub 2012 Dec 2. No abstract available.

161. Bioresorbable vascular scaffolds in cardiac allograft vasculopathy: a new therapeutic option.

Ribichini F, Pighi M, Faggian G, Vassanelli C.

Am J Med. 2013 Nov;126(11):e11-4. doi: 10.1016/j.amjmed.2013.05.025. No abstract available.

162. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXECutive RCT: evaluating XIENCE V in a multi vessel disease).

Ribichini F, Romano M, Rosiello R, La Vecchia L, Cabianca E, Caramanno G, Milazzo D, Loschiavo P, Rigattieri S, Musarò S, Pironi B, Fiscella A, Amico F, Indolfi C, Spaccarotella C, Bartorelli A, Trabattoni D, Della Rovere F, Rolandi A, Beqaraj F, Belli R, Sangiorgio P, Villani R, Berni A, Sheiban I, Lopera Quijada MJ, Cappi B, Ribaldi L, Vassanelli C; EXECUTIVE Trial Investigators.

JACC Cardiovasc Interv. 2013 Oct;6(10):1012-22. doi: 10.1016/j.jcin.2013.05.016. Epub 2013 Sep

163. Combined endovascular treatment for acute multi-distinct atherosclerotic disease.

Reimers B, Tomai F, Castriota F, **Ribichini F**; FRIENDS (Finalized Research In Endovascular Strategies) Study Group.

J Endovasc Ther. 2013 Aug;20(4):552-3. doi: 10.1583/13-4244C.1. No abstract available.

164. Transcatheter tricuspid valve implantation by femoral approach in trivalvular heart disease.

Ribichini F, Pesarini G, Feola M, Agostini M, Molinari G, Rossi A, Faggian G, Vassanelli C.

Am J Cardiol. 2013 Oct 1;112(7):1051-3. doi: 10.1016/j.amjcard.2013.05.043. Epub 2013 Aug 1.

165. Three-year follow-up of the MULTICentre evaluation of Single high-dose Bolus TiRoFiban versus Abciximab with Sirolimus-eluting STent or Bare-Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY).

Valgimigli M, Campo G, Gambetti S, Bolognese L, **Ribichini F**, Colangelo S, de Cesare N, Rodriguez AE, Russo F, Moreno R, Piva T, Sheiban I, Penzo C, Prati F, Nazzaro MS, Díaz Fernández JF, Vassanelli C, Parrinello G, Ferrari R; MULTICentre evaluation of Single high-dose bolus TiRoFiban versus Abciximab with sirolimus eluting sTent or Bare Metal Stent in Acute Myocardial Infarction study Investigators.

Int J Cardiol. 2013 Apr 30;165(1):134-41. doi: 10.1016/j.ijcard.2011.07.106. Epub 2011 Aug 24.

2014

166. The need for this supplement: beyond "exercises in style".

Ribichini F, Cuisset T.

EuroIntervention. 2014 Aug;10 Suppl T:T7-8. doi: 10.4244/EIJV10STA1. No abstract available.

167. Percutaneous coronary interventions during ST-segment elevation myocardial infarction: current status and future perspectives.

Diletti R, Yetgin T, Manintveld OC, Ligthart JM, Zivelonghi C, Zijlstra F, **Ribichini F**.

EuroIntervention. 2014 Aug;10 Suppl T:T13-22. doi: 10.4244/EIJV10STA4.

168. Virtual histology findings in rapid cardiac allograft vasculopathy progression and bioresorbable vascular scaffolds.

Ribichini F, Pighi M, Zivelonghi C, Faggian G, Vassanelli C.

Int J Cardiol. 2014 Sep;176(1):257-9. doi: 10.1016/j.ijcard.2014.06.056. Epub 2014 Jul 15. No abstract available.

169. Prognosis and disease progression in patients under 50 years old undergoing PCI: the CRAGS (Coronary aRtery diseAse in younG adultS) study.

Lautamäki A, Airaksinen KE, Kiviniemi T, Vinco G, **Ribichini F**, Gunn J, Anttila V, Heikkinen J, Korpilahti K, Karjalainen P, Kajander O, Eskola M, Ilveskoski E, Axelsson T, Gudbjartsson T, Jeppsson A, Biancari F.

Atherosclerosis. 2014 Aug;235(2):483-7. doi: 10.1016/j.atherosclerosis.2014.05.953. Epub 2014

170. Intracoronary optical coherence tomography: a review of clinical applications.

Zivelonghi C, Ghione M, Kilickesmez K, Loureiro RE, Foin N, Lindsay A, de Silva R, **Ribichini F**, Vassanelli C, Di Mario C.

J Cardiovasc Med (Hagerstown). 2014 Jul;15(7):543-53. doi: 10.2459/JCM

171. Comparison of 30-day and 5-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients aged ≤ 50 years (the Coronary aRtery diseAse in younG adultS Study).

Biancari F, Gudbjartsson T, Heikkinen J, Anttila V, Mäkikallio T, Jeppsson A, Thimour-Bergström L, Mignosa C, Rubino AS, Kuttala K, Gunn J, Wistbacka JO, Teittinen K, Korpilahti K, Onorati F, Faggian G, Vinco G, Vassanelli C, **Ribichini F**, Juvonen T, Axelsson TA, Sigurdsson AF, Karjalainen PP, Mennander A, Kajander O, Eskola M, Ilveskoski E, D'Oria V, De Feo M, Kiviniemi T, Airaksinen KE.

Am J Cardiol. 2014 Jul 15;114(2):198-205. doi: 10.1016/j.amjcard.2014.04.025. Epub 2014 May 2.

172. Coronary vasomotion one year after drug-eluting stent implantation: comparison of everolimus-eluting and paclitaxel-eluting coronary stents.

Hamilos M, **Ribichini F**, Ostojic MC, Ferrero V, Orlic D, Vassanelli C, Karanovic N, Sarno G, Cuisset T, Vardas PE, Wijns W.

J Cardiovasc Transl Res. 2014 Jun;7(4):406-12. doi: 10.1007/s12265-014-9568-2. Epub 2014 May

173. Asymptomatic severe aortic coarctation at old age.

Zivelonghi C, Pighi M, Perandini S, Vassanelli C, **Ribichini F**.

Int J Cardiol. 2014 May 15;173(3):e56-7. doi: 10.1016/j.ijcard.2014.03.096. Epub 2014 Mar 20.

174. Revascularization strategies in patients with combined carotid and coronary artery disease.

Tomai F, Castriota F, Reimers B, Borioni R, **Ribichini F**; FRIENDS Study Group.

J Am Coll Cardiol. 2014 Jun 24;63(24):2745-6. doi: 10.1016/j.jacc.2013.10.098. Epub 2014 Mar 26. No abstract available.

175. Drug-eluting stent or coronary artery bypass graft surgery in hemodialysis patients?

Ribichini F, Vassanelli C.

J Nephrol. 2014 Feb;27(1):7-9. doi: 10.1007/s40620-013-0010-7. Epub 2013 Dec 13. No abstract available.

176. Single-side renal sympathetic denervation to treat malignant refractory hypertension in a solitary kidney patient.

Ribichini F, Ferrara A, Pighi M, Pesarini G, Gambaro A, Valvo E, Lupo A, Vassanelli C.

J Nephrol. 2014;27:7-9.

177. Bail-out transcatheter aortic valve implantation to reduce severe acute aortic regurgitation in a failing homograft secondary to HeartMate II ventricular assistance device.

Ribichini F, Faggian G, Pesarini G, Milano A, Gottin L, Vassanelli C.

Cardiovasc Revasc Med. 2014 Jul-Aug;15(5):295-7. doi: 10.1016/j.carrev.2013.12.002. Epub 2013

178. "Valve in valve" implantation of two self-expandable transcatheter aortic valves in a patient with aortic root aneurysm and massive aortic regurgitation: "a new TAVI option".

Pesarini G, Bedogni F, **Ribichini F**.

Catheter Cardiovasc Interv. 2014 Apr 1;83(5):836-40. doi: 10.1002/ccd.25194. Epub 2013 Oct 23.

179. Tomai F, **Ribichini F**, De Luca L, Petrolini A, Ghini AS, Weltert L, Spaccarotella C, Proietti I, Trani C, Nudi F, Pighi M, Vassanelli C.

Circulation. 2014 Mar 11;129(10):1104-12. doi: 10.1161/CIRCULATIONAHA.113.005186. Epub 2013 Dec 19.

180. Different impact of sex on baseline characteristics and major periprocedural outcomes of transcatheter and surgical aortic valve interventions: Results of the multicenter Italian OBSERVANT Registry.

Onorati F, D'Errigo P, Barbanti M, Rosato S, Covello RD, Maraschini A, Ranucci M, Santoro G, Tamburino C, Grossi C, Santini F, Menicanti L, Seccareccia F; OBSERVANT Research Group.

J Thorac Cardiovasc Surg. 2014 May;147(5):1529-39. doi: 10.1016/j.jtcvs.2013.05.039. Epub 2013 Jul 13.

181. Capranzano P, Testa L, Tamburino C, Capodanno D, Biondi-Zoccai G, Longo G, Tomai F, **Ribichini F**, Indolfi C, Bartorelli AL, Petronio AS, Bedogni F, La Manna A, Francaviglia B, De Carlo M, Tamburino C. *G Ital Cardiol (Rome)*. 2014 Sep;15(9):475-81. doi: 10.1714/1640.17972. Italian.

182. Is TAVI superior to surgery in high-risk patients? Insight into the concept of individual risk assessment. Benfari G, Onorati F, Rossi A, Abbasciano R, Zivelonghi C, Salsano A, **Ribichini F**, Santini F, Vassanelli F, Mazzucco A, Faggian G. *Minerva Med*. 2014; 105:487-95.

183. ORAL iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: a patient-level meta-analysis of randomized trials.

Salvatore Cassese, MD, Giuseppe De Luca, MD, **Flavio Ribichini**, MD, Carmelo Cernigliaro, MD, Mara Sansa, MD, Francesco Versaci, MD, Iginio Proietti, MD, Goran Stankovic, MD, Sinisa Stojkovic, MD, Carlos Fernandez-Pereira, MD, Fabrizio Tomai, MD, Corrado Vassanelli, MD, David Antoniucci, MD, Patrick W. Serruys, MD, Adnan Kastrati, MD and Alfredo E. Rodriguez, MD. *Atherosclerosis* 2014;237:410-417

184. Real-time use of instantaneous wave-free ratio: Results of the ADVISE in-practice: An international, multicenter evaluation of instantaneous wave-free ratio in clinical practice.

Petraco R, Al-Lamee R, Gotberg M, Sharp A, Hellig F, Nijjer SS, Echavarría-Pinto M, van de Hoef TP, Sen S, Tanaka N, Van Belle E, Bojara W, Sakoda K, Mates M, Indolfi C, De Rosa S, Vrints CJ, Haine S, Yokoi H, **Ribichini FL**, Meuwissen M, Matsuo H, Janssens L, Katsumi U, Di Mario C, Escaned J, Piek J, Davies JE.

Am Heart J. 2014 Nov;168(5):739-48. doi: 10.1016/j.ahj.2014.06.022. Epub 2014 Jul 21.

185. Expanding TAVI options: elective rotational atherectomy during trans-catheter aortic valve implantation.

Piccoli A, Lunardi M, Ariotti S, Ferrero V, Vassanelli C, **Ribichini F**.

Cardiovasc Revasc Med. 2015;16:58-61 Review.

186. Defining the role of common variation in the genomic and biological architecture of adult human height.

Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, Chu AY, Estrada K, Luan J, Kutalik Z, Amin N, Buchkovich ML, Croteau-Chonka DC, Day FR, Duan Y, Fall T, Fehrmann R, Ferreira T, Jackson AU, Karjalainen J, Lo KS, Locke AE, Mägi R, Mihailov E, Porcu E, Randall JC, Scherag A, Vinkhuyzen AA, Westra HJ, Winkler TW, Workalemahu T, Zhao JH, Absher D, Albrecht E, Anderson D, Baron J, Beekman M, Demirkan A, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Fraser RM, Goel A, Gong J, Justice AE, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Lui JC, Mangino M, Mateo Leach I, Medina-Gomez C, Nalls MA, Nyholt DR, Palmer CD, Pasko D, Pechlivanis S, Prokopenko I, Ried JS, Ripke S, Shungin D, Stancáková A, Strawbridge RJ, Sung YJ, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostapchouk JV, Wang Z, Yengo L, Zhang W, Afzal U, Arnlöv J, Arscott GM, Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Blüher M, Bolton JL, Böttcher Y, Boyd HA, Bruinenberg M, Buckley BM, Buyske S, Caspersen IH, Chines PS, Clarke R, Claudi-Boehm S, Cooper M, Daw EW, De Jong PA, Deelen J, Delgado

G, Denny JC, Dhonukshe-Rutten R, Dimitriou M, Doney AS, Dörr M, Eklund N, Eury E, Folkersen L, Garcia ME, Geller F, Giedraitis V, Go AS, Grallert H, Grammer TB, Gräßler J, Grönberg H, de Groot LC, Groves CJ, Haessler J, Hall P, Haller T, Hallmans G, Hannemann A, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q, Hemani G, Henders AK, Hillege HL, Hlatky MA, Hoffmann W, Hoffmann P, Holmen O, Houwing-Duistermaat JJ, Illig T, Isaacs A, James AL, Jeff J, Johansen B, Johansson Å, Jolley J, Juliusdottir T, Junttila J, Kho AN, Kinnunen L, Klopp N, Kocher T, Kratzer W, Lichtner P, Lind L, Lindström J, Lobbens S, Lorentzon M, Lu Y, Lyssenko V, Magnusson PK, Mahajan A, Maillard M, McArdle WL, McKenzie CA, McLachlan S, McLaren PJ, Menni C, Merger S, Milani L, Moayyeri A, Monda KL, Morken MA, Müller G, Müller-Nurasyid M, Musk AW, Narisu N, Nauck M, Nolte IM, Nöthen MM, Oozageer L, Pilz S, Rayner NW, Renstrom F, Robertson NR, Rose LM, Roussel R, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Schunkert H, Scott RA, Sehmi J, Seufferlein T, Shi J, Silventoinen K, Smit JH, Smith AV, Smolonska J, Stanton AV, Stirrups K, Stott DJ, Stringham HM, Sundström J, Swertz MA, Syvänen AC, Tayo BO, Thorleifsson G, Tyrer JP, van Dijk S, van Schoor NM, van der Velde N, van Heemst D, van Oort FV, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Waldenberger M, Wennauer R, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Bergmann S, Biffar R, Blangero J, Boomsma DI, Bornstein SR, Bovet P, Brambilla P, Brown MJ, Campbell H, Caulfield MJ, Chakravarti A, Collins R, Collins FS, Crawford DC, Cupples LA, Danesh J, de Faire U, den Ruijter HM, Erbel R, Erdmann J, Eriksson JG, Farrall M, Ferrannini E, Ferrières J, Ford I, Forouhi NG, Forrester T, Gansevoort RT, Gejman PV, Gieger C, Golay A, Gottesman O, Gudnason V, Gyllensten U, Haas DW, Hall AS, Harris TB, Hattersley AT, Heath AC, Hengstenberg C, Hicks AA, Hindorff LA, Hingorani AD, Hofman A, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Jacobs KB, Jarvelin MR, Jousilahti P, Jula AM, Kaprio J, Kastelein JJ, Kayser M, Kee F, Keinanen-Kiukaanniemi SM, Kiemenev LA, Kooner JS, Kooperberg C, Koskinen S, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lupoli S, Madden PA, Männistö S, Manunta P, Marette A, Matisse TC, McKnight B, Meitinger T, Moll FL, Montgomery GW, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Ouwehand WH, Pasterkamp G, Peters A, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ritchie M, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PE, Sebert S, Sever P, Shuldiner AR, Sinisalo J, Steinthorsdottir V, Stolk RP, Tardif JC, Tönjes A, Tremblay A, Tremoli E, Virtamo J, Vohl MC; Electronic Medical Records and Genomics (eMEMERGE) Consortium; MIGen Consortium; PAGEGE Consortium; LifeLines Cohort Study, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PI, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hayes MG, Hui J, Hunter DJ, Hveem K, Jukema JW, Kaplan RC, Kivimäki M, Kuh D, Laakso M, Liu Y, Martin NG, März W, Melbye M, Moebus S, Munroe PB, Njølstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Pérusse L, Peters U, Powell JE, Power C, Quertermous T, Rauramaa R, Reinmaa E, Ridker PM, Rivadeneira F, Rotter JI, Saaristo TE, Saleheen D, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Strauch K, Stumvoll M, Tuomilehto J, Uusitupa M, van der Harst P, Völzke H, Walker M, Wareham NJ, Watkins H, Wichmann HE, Wilson JF, Zanen P, Deloukas P, Heid IM, Lindgren CM, Mohlke KL, Speliotes EK, Thorsteinsdottir U, Barroso I, Fox CS, North KE, Strachan DP, Beckmann JS, Berndt SI, Boehnke M, Borecki IB, McCarthy MI, Metspalu A, Stefansson K, Uitterlinden AG, van Duijn CM, Franke L, Willer CJ, Price AL, Lettre G, Loos

RJ, Weedon MN, Ingelsson E, O'Connell JR, Abecasis GR, Chasman DI, Goddard ME, Visscher PM, Hirschhorn JN, Frayling TM.
Nat Genet. 2014 Nov;46(11):1173-86. doi: 10.1038/ng.3097. Epub 2014 Oct 5

2015

187. Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group.

Burzotta F, Trani C, Doshi SN, Townend J, van Geuns RJ, Hunziker P, Schieffer B, Karatolios K, Møller JE, Ribichini FL, Schäfer A, Henriques JP.

Int J Cardiol. 2015 Jul 30;201:684-691. doi: 10.1016/j.ijcard.2015.07.065. [Epub ahead of print] Review.

188. Tpeak-to-Tend/QT is an independent predictor of early ventricular arrhythmias and arrhythmic death in anterior ST elevation myocardial infarction patients.

Mugnai G, Benfari G, Fede A, Rossi A, Chierchia GB, Vassanelli F, Menegatti G, Ribichini FL.

Eur Heart J Acute Cardiovasc Care. 2015 Jul 30. pii: 2048872615598616. [Epub ahead of print]

189. Stent Type and Risk of Late Cerebral Events After Carotid Artery Stenting.

Pacchioni A, **Ribichini F**, Reimers B.

J Am Coll Cardiol. 2015 Jul 28;66(4):490. doi: 10.1016/j.jacc.2015.04.074. No abstract available.

190. How should I treat an acute anterior myocardial infarction associated with a myocardial rupture? Between the devil and the deep blue sea.

Amabile N, Pascal J, Rohnean A, Raoux F, Nottin R, Caussin C, Vrints CJ, Ribichini FL.

EuroIntervention. 2015 Jun 22;11(2):e1-7. doi: 10.4244/EIJV11I2A46. No abstract available.

191. iFR-FFR comparison in daily practice: a single-center, prospective, online assessment.

Fede A, Zivelonghi C, Benfari G, Pesarini G, Pighi M, Ferrara A, Piccoli A, Ariotti S, Ferrero V, Mura DD, Battistoni M, Vassanelli C, **Ribichini F**.

J Cardiovasc Med (Hagerstown). 2015 Sep;16(9):625-31. doi: 10.2459/JCM.0000000000000272.

192. European expert consensus on rotational atherectomy.

Barbato E, Carrié D, Dardas P, Fajadet J, Gaul G, Haude M, Khashaba A, Koch K, Meyer-Gessner M, Palazuelos J, Reczuch K, Ribichini FL, Sharma S, Sipötz J, Sjögren I, Suetsch G, Szabó G, Valdés-Chávarri M, Vaquerizo B, Wijns W, Windecker S, de Belder A, Valgimigli M, Byrne RA, Colombo A, Di Mario C, Latib A, Hamm C.

EuroIntervention. 2015 May;11(1):30-6. doi: 10.4244/EIJV11I1A6.

193. Position paper on the theoretical basis, practical application and health economic evaluation of the functional assessment of coronary lesions endorsed by the Italian Society of

Invasive Cardiology (SICI-GISE)

Bedogni F, Indolfi C, **Ribichini F**, Verna E, Leone AM, Polimeni A, Bollati M, Biondi-Zoccai G, Testa L, Berti S; Italian Society of Invasive Cardiology (SICI-GISE). *G Ital Cardiol (Rome)*. 2015 Feb;16(2):116-28. doi: 10.1714/1798.19590. Italian.

194. Bypass surgery versus percutaneous coronary intervention: evidence, indications and patient preference according to the latest European guidelines on myocardial revascularization

Ribichini F, Pighi M, Vassanelli C.

G Ital Cardiol (Rome). 2015 Feb;16(2):71-6. doi: 10.1714/1798.19574. Italian. No abstract available.

195 Genetic studies of body mass index yield new insights for obesity biology.

Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Mägi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Hua Zhao J, Zhao W, Chen J, Fehrmann R, Hedman ÅK, Karjalainen J, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Mateo Leach I, Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stančáková A, Strawbridge RJ, Ju Sung Y, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Ärnlöv J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Blüher M, Böhringer S, Bonnycastle LL, Böttcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Ida Chen YD, Clarke R, Daw EW, de Craen AJ, Delgado G, Dimitriou M, Doney AS, Eklund N, Estrada K, Eury E, Folkersen L, Fraser RM, Garcia ME, Geller F, Giedraitis V, Gigante B, Go AS, Golay A, Goodall AH, Gordon SD, Gorski M, Grabe HJ, Grallert H, Grammer TB, Gräßler J, Grönberg H, Groves CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q, Hengstenberg C, Holmen O, Hottenga JJ, James AL, Jeff JM, Johansson Å, Jolley J, Juliusdottir T, Kinnunen L, Koenig W, Koskenvuo M, Kratzer W, Laitinen J, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindström J, Sin Lo K, Lobbens S, Lorbeer R, Lu Y, Mach F, Magnusson PK, Mahajan A, McArdle WL, McLachlan S, Menni C, Merger S, Mihailov E, Milani L, Moayyeri A, Monda KL, Morken MA, Mulas A, Müller G, Müller-Nurasyid M, Musk AW, Nagaraja R, Nöthen MM, Nolte IM, Pilz S, Rayner NW, Renstrom F, Rettig R, Ried JS, Ripke S, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Scott WR, Seufferlein T, Shi J, Vernon Smith A, Smolonska J, Stanton AV, Steinthorsdottir V, Stirrups K, Stringham HM, Sundström J, Swertz MA, Swift AJ, Syvänen AC, Tan ST, Tayo BO, Thorand B, Thorleifsson G, Tyrer JP, Uh HW, Vandenput L, Verhulst FC, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Warren HR, Waterworth D, Weedon MN, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q; LifeLines Cohort Study, Brennan EP, Choi M, Dastani Z, Drong AW, Eriksson P, Franco-Cereceda A, Gådin JR, Gharavi AG, Goddard ME, Handsaker RE, Huang J, Karpe F, Kathiresan S, Keildson S, Kiryluk K, Kubo M, Lee JY, Liang L, Lifton RP, Ma B, McCarroll SA, McKnight AJ, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Okada Y, Perry JR, Dorajoo R, Reinmaa E, Salem RM, Sandholm N, Scott RA, Stolk L, Takahashi A, Tanaka T, Van't Hooft FM,

Vinkhuyzen AA, Westra HJ, Zheng W, Zondervan KT; ADIPOGen Consortium; AGEN-BMI Working Group; CARDIOGRAMplusC4D Consortium; CKDGen Consortium; GLGC; ICBP; MAGIC Investigators; MuTHER Consortium; MIGen Consortium; PAGE Consortium; ReproGen Consortium; GENIE Consortium; International Endogene Consortium, Heath AC, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Bovet P, Campbell H, Caulfield MJ, Cesana G, Chakravarti A, Chasman DI, Chines PS, Collins FS, Crawford DC, Cupples LA, Cusi D, Danesh J, de Faire U, den Ruijter HM, Dominiczak AF, Erbel R, Erdmann J, Eriksson JG, Farrall M, Felix SB, Ferrannini E, Ferrières J, Ford I, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gejman PV, Gieger C, Gottesman O, Gudnason V, Gyllenstein U, Hall AS, Harris TB, Hattersley AT, Hicks AA, Hindorf LA, Hingorani AD, Hofman A, Homuth G, Hovingh GK, Humphries SE, Hunt SC, Hyppönen E, Illig T, Jacobs KB, Jarvelin MR, Jöckel KH, Johansen B, Jousilahti P, Jukema JW, Jula AM, Kaprio J, Kastelein JJ, Keinanen-Kiukkaanniemi SM, Kiemeny LA, Knekt P, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lyssenko V, Männistö S, Marette A, Matise TC, McKenzie CA, McKnight B, Moll FL, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Madden PA, Pasterkamp G, Peden JF, Peters A, Postma DS, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Rioux JD, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schunkert H, Schwarz PE, Sever P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tönjes A, Trégouët DA, Tremblay A, Tremoli E, Virtamo J, Vohl MC, Völker U, Waeber G, Willemsen G, Witteman JC, Zillikens MC, Adair LS, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bornstein SR, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PI, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hui J, Hunter DJ, Hveem K, Kaplan RC, Kivimäki M, Kuh D, Laakso M, Liu Y, Martin NG, März W, Melbye M, Metspalu A, Moebus S, Munroe PB, Njølstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Pérusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sattar N, Schadt EE, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Thorsteinsdóttir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Walker M, Wallaschofski H, Wareham NJ, Watkins H, Weir DR, Wichmann HE, Wilson JF, Zanen P, Borecki IB, Deloukas P, Fox CS, Heid IM, O'Connell JR, Strachan DP, Stefansson K, van Duijn CM, Abecasis GR, Franke L, Frayling TM, McCarthy MI, Visscher PM, Scherag A, Willer CJ, Boehnke M, Mohlke KL, Lindgren CM, Beckmann JS, Barroso I, North KE, Ingelsson E, Hirschhorn JN, Loos RJ, Speliotes EK.

Nature. 2015 Feb 12;518(7538):197-206. doi: 10.1038/nature14177. PMID: 25673413

196. Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS). Study design and rationale.

Testa L, Biondi Zoccai G, Tomai F, **Ribichini F**, Indolfi C, Tamburino C, Bartorelli A, Petronio AS, Bedogni F, De Carlo M.

J Cardiovasc Med (Hagerstown). 2015 Mar;16(3):253-8. doi: 10.2459/JCM.0000000000000219.

197. Tamburino C, Barbanti M, D'Errigo P, Ranucci M, Onorati F, Covello RD, Santini F, Rosato S, Santoro G, Fusco D, Grossi C, Seccareccia F; OBSERVANT Research Group. 1-Year Outcomes After Transfemoral Transcatheter or Surgical Aortic Valve Replacement: Results From the Italian OBSERVANT Study.

J Am Coll Cardiol. 2015 Aug 18;66(7):804-12. doi: 10.1016/j.jacc.2015.06.013

2016

198. Scarsini R, Prioli MA, Milano EG, Castellani C, Pesarini G, Assael BM, Vassanelli C, Ribichini FL.

Hemodynamic predictors of long term survival in end stage cystic fibrosis.

Int J Cardiol. 2016 Jan 1;202:221-5. doi: 10.1016/j.ijcard.2015.09.009.

199. Pighi M, Tomai F, Petrolini A, de Luca L, Tarantini G, Barioli A, Colombo P, Klugmann S, Ferlini M, Ormezzano MF, Loi B, Calabrò P, Bianchi RM, Faggian G, Forni A, Vassanelli C, Valgimigli M, **Ribichini F.**

Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study.

J Cardiovasc Transl Res. 2016 Feb;9(1):40-8. doi: 10.1007/s12265-015-9665-x.

200. Maggio S, Zanetti C, Pesarini G, Zivelonghi C, Piccoli A, Gambaro A, Scarsini R, Cuman M, Vassanelli C, **Ribichini F.**

Immediate and long-term clinical performance of bioresorbable vascular scaffolds in a real world population.

Minerva Cardioangiol. 2016 Aug;64(4):404-10.

201. Pesarini G, Lunardi M, Ederle F, Zivelonghi C, Scarsini R, Gambaro A, Lupo A, Vassanelli C, **Ribichini F.**

Long-Term (3 Years) Prognosis of Contrast-Induced Acute Kidney Injury After Coronary Angiography.

Am J Cardiol. 2016 Jun 1;117(11):1741-6. doi: 10.1016/j.amjcard.2016.03.008.

202. Repeat revascularization: Percutaneous coronary intervention after coronary artery bypass graft surgery.

Scarsini R, Zivelonghi C, Pesarini G, Vassanelli C, **Ribichini FL.**

Cardiovasc Revasc Med. 2016 Jun;17(4):272-8. doi: 10.1016/j.carrev.2016.04.007. Review.

203. **Ribichini F.**

Rationale for the use of bioresorbable vascular scaffolds. Why bioresorbable technology is the future of endovascular therapeutics.

Minerva Cardioangiol. 2016 Aug;64(4):399-403. No abstract available.

204. Benfari G, Dandale R, Rossi A, Onorati F, Mugnai G, **Ribichini F**, Temporelli PL, Vassanelli C.

Functional mitral regurgitation: are we treating the real target?

J Cardiovasc Med (Hagerstown). 2016 Nov;17(11):767-73. doi: 10.2459/JCM.0000000000000429.

205. Salizzoni S, D'Onofrio A, Agrifoglio M, Colombo A, Chieffo A, Cioni M, Besola L, Regesta T, Rapetto F, Tarantini G, Napodano M, Gabbieri D, Saia F, Tamburino C, **Ribichini F**, Cugola D, Aiello M, Sanna F, Iadanza A, Pompei E, Stefano P, Cappai A, Minati A, Cassese M, Martinelli GL, Agostinelli A, Fiorilli R, Casilli F, Reale M, Bedogni F, Petronio AS, Mozzillo RA, Bonmassari R, Briguori C, Liso A, Sardella G, Bruschi G, Fiorina C, Filippini C, Moretti C, D'Amico M, La Torre M, Conrotto F, Di Bartolomeo R, Gerosa G, Rinaldi M; TAVI Team.

Early and mid-term outcomes of 1904 patients undergoing transcatheter balloon-expandable valve implantation in Italy: results from the Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER).

Eur J Cardiothorac Surg. 2016 Dec;50(6):1139-1148. doi: 10.1093/ejcts/ezw218.

206. Conrotto F, D'Ascenzo F, D'Onofrio A, Agrifoglio M, Chieffo A, Cioni M, Regesta T, Tarantini G, Gabbieri D, Saia F, Tamburino C, **Ribichini F**, Cugola D, Aiello M, Sanna F, Iadanza A, Pompei E, Stolcova M, Cappai A, Minati A, Cassese M, Martinelli GL, Agostinelli A, Gerosa G, Gaita F, Rinaldi M, Salizzoni S.

Predictive ability of the CHADS2 and CHA2DS2-VASc scores for stroke after transcatheter aortic balloon-expandable valve implantation: an Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER) sub-analysis.

Eur J Cardiothorac Surg. 2016 Nov;50(5):867-873.

207. Lunardi M, Pesarini G, Zivelonghi C, Piccoli A, Geremia G, Ariotti S, Rossi A, Gambaro A, Gottin L, Faggian G, Vassanelli C, **Ribichini F**.

Clinical outcomes of transcatheter aortic valve implantation: from learning curve to proficiency.

Open Heart. 2016 Aug 16;3(2):e000420. doi: 10.1136/openhrt-2016-000420.

208. Pighi M, Tomai F, **Ribichini F**.

J Cardiovasc Transl Res. 2016 Dec;9(5-6):461-462. No abstract available.

209. Pesarini G, Scarsini R, Zivelonghi C, Piccoli A, Gambaro A, Gottin L, Rossi A, Ferrero V, Vassanelli C, **Ribichini F**.

Functional Assessment of Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Implantation: Influence of Pressure Overload on the Evaluation of Lesions Severity.

Circ Cardiovasc Interv. 2016 Nov;9(11). pii: e004088.

210. Coronary Catheterization and Percutaneous Interventions After Transcatheter Aortic Valve Implantation.

Zivelonghi C, Pesarini G, Scarsini R, Lunardi M, Piccoli A, Ferrero V, Gottin L, Vassanelli C, **Ribichini F**.

Am J Cardiol. 2016 Nov 16. pii: S0002-9149(16)31821-5. doi: 10.1016/j.amjcard.2016.10.046.

211. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.

Stone GW, Sabik JF, Serruys PW, Simonton CA, Généreux P, Puskas J, Kandzari DE, Morice MC, Lembo N, Brown WM 3rd, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Pagé P, Dressler O,

Kosmidou I, Mehran R, Pocock SJ, Kappetein AP; EXCEL Trial Investigators.
N Engl J Med. 2016 Dec 8;375(23):2223-2235. Epub 2016 Oct 31.

2017

212. Bartunek J, Terzic A, Davison BA, Filippatos GS, Radovanovic S, Beleslin B, Merkely B, Musialek P, Wojakowski W, Andreka P, Horvath IG, Katz A, Dolatabadi D, El Nakadi B, Arandjelovic A, Edes I, Seferovic PM, Obradovic S, Vanderheyden M, Jagic N, Petrov I, Atar S, Halabi M, Gelev VL, Shochat MK, Kasprzak JD, Sanz-Ruiz R, Heyndrickx GR, Nyolczas N, Legrand V, Guédès A, Heyse A, Moccetti T, Fernandez-Aviles F, Jimenez-Quevedo P, Bayes-Genis A, Hernandez-Garcia JM, **Ribichini F**, Gruchala M, Waldman SA, Teerlink JR, Gersh BJ, Povsic TJ, Henry TD, Metra M, Hajjar RJ, Tendera M, Behfar A, Alexandre B, Seron A, Stough WG, Sherman W, Cotter G, Wijns W; CHART Program. Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.
Eur Heart J. 2017 Mar 1;38(9):648-660. doi: 10.1093/eurheartj/ehw543.

213. Benfari G, Rossi A, Geremia G, Vinco G, Zivelonghi C, Milano AD, Gottin L, **Ribichini FL**, Onorati F, Faggian G.
Optimizing the role of transthoracic echocardiography to improve the cardiovascular risk stratification: the dream of subclinical coronary artery disease detection.
Minerva Med. 2017 Jul 21. doi: 10.23736/S0026-4806.17.05311-3. [Epub ahead of print]

214. Danese A, Stegagno C, Tomelleri G, Piccoli A, Turri G, Carletti M, Variola A, Anselmi M, Mazzucco S, Ferrara A, Bovi P, Micheletti N, Cappellari M, Monaco S, Vassanelli C, **Ribichini F**; Verostroke Group.
Clinical outcomes of secondary prevention strategies for young patients with cryptogenic stroke and patent foramen ovale.
Acta Cardiol. 2017 Aug;72(4):410-418. doi: 10.1080/00015385.2017.1307668. Epub 2017 Jul 14.

215. Scarsini R, Pesarini G, Zivelonghi C, Piccoli A, Ferrero V, Lunardi M, Barbierato M, Caprioglio F, Vassanelli C, **Ribichini F**.
Coronary physiology in patients with severe aortic stenosis: Comparison between fractional flow reserve and instantaneous wave-free ratio.
Int J Cardiol. 2017 Sep 15;243:40-46. doi: 10.1016/j.ijcard.2017.05.117. Epub 2017 Jun 5.

216. Zivelonghi C, Ghione M, Benfari G, Cuman M, Fede A, Lunardi M, Cordone S, Botta M, Pacchioni A, Bellone P, Reimers B, **Ribichini FL**.
Drug-coated balloon: Long-term outcome from a real world three-center experience.
J Interv Cardiol. 2017 Aug;30(4):318-324. doi: 10.1111/joic.12391. Epub 2017 Jun 5.

217. **Ribichini F**, Scarsini R, Zanetti C, Pesarini G.
First Observation of a "Golden Tube" After Complete Resorption of a Bioresorbable Vascular

Scaffold in a Transplanted Patient With Cardiac Allograft Vasculopathy.

JACC Cardiovasc Interv. 2017 Jun 26;10(12):1270-1272. doi: 10.1016/j.jcin.2017.03.040.

218. Testa L, De Carlo M, Petrolini A, Rapetto C, Varbella F, Cortese B, Gabrielli G, Geraci S, Loi B, Boccuzzi G, Tarantini G, Fischetti D, Calabria P, Tomai F, **Ribichini F**, Tamburino C, Indolfi C, Bartorelli AL, Petronio AS, Bedogni F.

Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III.

EuroIntervention. 2017 Jul 20;13(4):432-439. doi: 10.4244/EIJ-D-17-00254.

219. Testa L, De Carlo M, Petrolini A, Rapetto C, Varbella F, Cortese B, Gabrielli G, Geraci S, Loi B, Boccuzzi G, Tarantini G, Fischetti D, Calabria P, Tomai F, **Ribichini F**, Tamburino C, Indolfi C, Bartorelli AL, Petronio AS, Bedogni F.

One-year clinical results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT-DISAPPEARS).

EuroIntervention. 2017 Jul 20;13(4):424-431. doi: 10.4244/EIJ-D-17-00246.

220. Di Gioia G, Scarsini R, Strisciuglio T, De Biase C, Zivelonghi C, Franco D, De Bruyne B, **Ribichini F**

Correlation between Angiographic and Physiologic Evaluation of Coronary Artery Narrowings in Patients With Aortic Valve Stenosis.

Am J Cardiol. 2017 Jul 1;120(1):106-110. doi: 10.1016/j.amjcard.2017.03.250. Epub 2017

221. Maggio S, Gambaro A, Scarsini R, **Ribichini F**.

Preventive left main and right coronary artery stenting to avoid coronary ostia occlusion in high-risk stentless valve-in-valve transcatheter aortic valve implantation.

Interact Cardiovasc Thorac Surg. 2017 Mar 31. doi: 10.1093/icvts/ivx068. [Epub ahead of print]

222. Conrotto F, Salizzoni S, Andreis A, D'Ascenzo F, D'Onofrio A, Agrifoglio M, Chieffo A, Colombo A, Rapetto F, Santini F, Tarantini G, Gabbieri D, Savini C, Immè S, **Ribichini F**, Valsecchi O, Aiello M, Lixi G, Iadanza A, Pompei E, Stolcova M, Ornaghi D, Minati A, Cassese M, Martinelli GL, Sbarra P, Agostinelli A, Audo A, Pieroni A, Fiorilli R, Gerosa G, Rinaldi M, Gaita F.

Transcatheter Aortic Valve Implantation in Patients With Advanced Chronic Kidney Disease.

Am J Cardiol. 2017 May 1;119(9):1438-1442. doi: 10.1016/j.amjcard.2017.01.042. Epub

223. Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, Bhindi R, Lehman SJ, Walters D, Sapontis J, Janssens L, Vrints CJ, Khashaba A, Laine M, Van Belle E, Krackhardt F, Bojara W, Going O, Härle T, Indolfi C, Niccoli G, **Ribichini F**, Tanaka N, Yokoi H, Takashima H, Kikuta Y, Erglis A, Vinhas H, Canas Silva P, Baptista SB, Alghamdi A, Hellig F, Koo BK, Nam CW, Shin ES, Doh JH, Brugaletta S, Alegria-Barrero E, Meuwissen M, Piek JJ, van Royen N, Sezer M, Di Mario C, Gerber RT, Malik IS, Sharp ASP, Talwar S, Tang K, Samady H, Altman J, Seto AH, Singh J, Jeremias A, Matsuo H, Kharbanda RK, Patel MR, Serruys P, Escaned J.

Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI.

N Engl J Med. 2017 May 11;376(19):1824-1834. doi: 10.1056/NEJMoa1700445.

224. Pernigo M, Canneto B, Betta D, Molinari G, **Ribichini F**, Zannini G, Vassanelli C, Rossi A.

Dyspnea following thoracostomy closure after right pneumonectomy: An uncommon echocardiographic diagnosis and therapeutic approach.

Echocardiography. 2017 May;34(5):782-785. doi: 10.1111/echo.13505. Epub 2017 Mar 14.

225. Scarsini R, Lunardi M, Pesarini G, Castriota F, Feola M, Ferrero V, Faggian G, Vassanelli C, **Ribichini F**.

Long-term follow-up after trans-catheter tricuspid valve-in-valve replacement with balloon-expandable aortic valves.

Int J Cardiol. 2017 May 15;235:141-146. doi: 10.1016/j.ijcard.2017.02.076. Epub 2017 Feb

226. Colli A, Besola L, Salizzoni S, Gregori D, Tarantini G, Agrifoglio M, Chieffo A, Regesta T, Gabbieri D, Saia F, Tamburino C, **Ribichini F**, Valsecchi O, Loi B, Iadanza A, Stolcova M, Minati A, Martinelli G, Bedogni F, Petronio A, Dallago M, Cappai A, D'Onofrio A, Gerosa G, Rinaldi M.

Does pre-existing aortic regurgitation protect from death in patients who develop paravalvular leak after TAVI?

Int J Cardiol. 2017 Apr 15;233:52-60. doi: 10.1016/j.ijcard.2017.02.005. Epub 2017 Feb 4.